

Review

# Actin Cytoskeleton and Regulation of TGF $\beta$ Signaling: Exploring Their Links

Roberta Melchionna <sup>1,†</sup>, Paola Trono <sup>1,2,†</sup>, Annalisa Tocci <sup>1</sup> and Paola Nisticò <sup>1,\*</sup>

<sup>1</sup> Tumor Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, via Chianesi 53, 00144 Rome, Italy; roberta.melchionna@ifogov.it (R.M.); paola.trono@ifogov.it (P.T.); annalisa.tocci@ifogov.it (A.T.)

<sup>2</sup> Institute of Biochemistry and Cell Biology, National Research Council, via Ramarini 32, 00015 Monterotondo Scalo, Rome, Italy

\* Correspondence: paola.nistico@ifogov.it; Tel.: +39-0652662539

† These authors contributed equally to this paper.

**Abstract:** Human tissues, to maintain their architecture and function, respond to injuries by activating intricate biochemical and physical mechanisms that regulates intercellular communication crucial in maintaining tissue homeostasis. Coordination of the communication occurs through the activity of different actin cytoskeletal regulators, physically connected to extracellular matrix through integrins, generating a platform of biochemical and biomechanical signaling that is deregulated in cancer. Among the major pathways, a controller of cellular functions is the cytokine transforming growth factor  $\beta$  (TGF $\beta$ ), which remains a complex and central signaling network still to be interpreted and explained in cancer progression. Here, we discuss the link between actin dynamics and TGF $\beta$  signaling with the aim of exploring their aberrant interaction in cancer.

**Keywords:** actin cytoskeleton; actin-binding proteins; TGF $\beta$ ; extracellular matrix; tumor microenvironment



**Citation:** Melchionna, R.; Trono, P.; Tocci, A.; Nisticò, P. Actin Cytoskeleton and Regulation of TGF $\beta$  Signaling: Exploring Their Links. *Biomolecules* **2021**, *11*, 336. <https://doi.org/10.3390/biom11020336>

Academic Editor: Vladimir N. Uversky

Received: 19 January 2021  
Accepted: 20 February 2021  
Published: 23 February 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Actin dynamics critically affect different aspects of human health and disease, ranging from embryonic development to wound repair, inflammation, and cancer [1]. Each of these complex processes requires that a coordinated formation of multiple actin-based structures occurs. Actin dynamics refer to dynamic rearrangements of actin-based structures whose spatial and temporal control generates the physical force that enables cell motile functions. Almost all the cells, from prokaryotic to multicellular organisms, have the ability to sense a wide range of physical and chemical signals from the surrounding environment and elaborate specific responses by adjusting their cytoskeletal organization, and hence their shape and motility [2].

A fine regulation of actin filament dynamics guarantees plasticity and dynamicity of actin cytoskeleton that allows the cell to elaborate the adequate cytoskeleton-based responses to stimuli. Although for a long time considered merely regulators of cell mechanical properties, actin dynamics have emerged as platforms for signaling pathways [3]. Notably, actin dynamics have been linked to gene transcription, pointing out mechanisms that communicate the cytoplasmic actin status to the nuclear genome [4].

The transforming growth factor  $\beta$  (TGF $\beta$ ) family encompasses cytokines with widespread and diverse biological effects. Essentially, all cells perceive TGF $\beta$  family signals and elaborate responses that affect cell proliferation, differentiation, communication, adhesion, movement, metabolism, and death. The wide-ranging nature of biological signals elicited by TGF $\beta$  underlies the complexity of this pathway, which mediates fate decisions during development, tissue homeostasis and regeneration, tumorigenesis, fibrosis, and the immune response [5–11].

The effects of the cytokines of TGF $\beta$  family are mediated by a combinatorial set of ligands and receptors and can differ dramatically depending on the cellular context [12]. The TGF $\beta$  signaling pathway is critically influenced by mechanical cues including extracellular matrix (ECM) stiffness, cell–cell adhesion, cell–matrix adhesion, cell density, cell tension and cell polarity [13] all processes guaranteed by the plasticity and dynamicity of actin cytoskeleton.

While the role of TGF $\beta$  signaling in the organization of actin cytoskeleton architecture has been extensively investigated, the ways in which actin cytoskeleton dynamics modulate TGF $\beta$  signaling have just started to emerge.

Herein, we provide a brief overview of the actin dynamics and TGF $\beta$  signaling pathway and present evidence to disclose their interaction, starting from ECM, through the plasma membrane up to the nucleus all steps where actin and TGF $\beta$  signaling crosstalk and affect cancer.

## 2. Actin Cytoskeleton: Architecture and Signaling

### 2.1. Actin Cytoskeleton Architecture and Dynamics

Actin, one of the most abundant and highly conserved proteins in eukaryotic cells, is a 42 kDa adenosine-5'-triphosphate (ATP)-binding protein that cycles from monomeric globular actin (G-actin) to polymeric filamentous actin (F-actin) in a complex process governed by many different actin-binding proteins (ABPs) [14].

Actin polymerization gives rise to filaments with different types of organization: branched and cross-linked networks, parallel bundles, and anti-parallel contractile structures located in specific subcellular compartments [15]. Branched and crosslinked networks of lamellipodia at the front of the cell represent the major engine of cell movement, along with aligned bundles of filopodia. A thin layer of actin forms the cell cortex at the plasma membrane, contributing to the maintenance of cell shape. Interspersed in the rest of the cell, the actin scaffold is made up of a three-dimensional network of cross-linked filaments and contractile bundles, including stress fibers that connect the cell cytoskeleton to the extracellular matrix via focal adhesion sites. Incorporated within the actin network are filaments of the molecular motor protein myosin that produce contraction in the cell body and tension at focal adhesion [15].

This organization makes the cytoskeleton highly responsive to stimuli and regulates dynamic cell behavior [1]. The activity balance of actin assembly factors has to be achieved to ensure the main functions of the cytoskeletal system: to generate force, to create structural scaffolds, and to act as tracks for motor proteins [16]. At a molecular level, actin filament turnover proceeds through finely tuned steps: monomer sequestration or delivery, filament nucleation, elongation, capping, severing, or depolymerization [14]. The rate and direction of polymerization, as well as the shape of the newly generated filament, are determined by local intracellular concentrations of ATP-bound G-actin and by the activity of ABPs [14].

### 2.2. Actin Cytoskeleton Regulatory Proteins

ABPs act as key players of actin dynamics, participating in diverse processes ranging from maintaining a large pool of actin monomers available for polymerization, to initiating polymerization, nucleating assembly of new filaments, promoting elongation, capping the ends of polymers to terminate elongation, severing, and crosslinking of filaments [14]. G-actin-binding proteins maintain high concentrations of free G-actin by preventing spontaneous nucleation of new filaments while barbed end capping proteins prevent their elongation.

Profilin binds weakly to ATP-actin at the barbed ends, catalyzes nucleotide exchange by rapidly dissociating adenosine-5'-diphosphate (ADP) from newly depolymerized actin monomers, allowing further barbed end elongation [17]. To maintain the actin monomer pool, profilin cooperates with the capping protein (CP) [18]. Furthermore, profilin promotes elongation of barbed ends by delivering actin to polyproline sequences of proteins such as

formins and Ena/VASP. At the same time, profilin prevents spontaneous actin nucleation and elongation at the actin pointed ends [14].

To initiate actin filament polymerization in a controlled manner, cells use an Arp2/3 complex to produce actin filament branches, formins to initiate unbranched filaments, and proteins with tandem WH-2 domains to form other filaments [14].

Severing proteins such as cofilin and members of the gelsolin family promote actin filament turnover by disassembling actin filaments, and producing free barbed ends. A large family of cross-linking proteins operate to physically connect actin filaments and stabilize higher-order structures, such as bundles of filaments in microvilli, filopodia, and cytoplasmic cables, as well as networks of actin filaments [19,20].

Among the actin cytoskeleton regulatory proteins, we focus on Ena/VASP, critical players in metastatic cancer progression. Ena/VASP proteins promote actin elongation via antagonizing actin filament capping [21]. The Ena/VASP family encompasses three mammalian family members: VASP (vasodilator-stimulated phosphoprotein), MENA (mammalian ENA homolog), and EVL (Ena-VASP-like), sharing a conserved domain structure. Each family member consists of an N-terminal EVH1 domain, a central proline-rich region, and a C-terminal EVH2 domain [22]. The EVH2 domain, which contains G-actin and F-actin-binding sites, is responsible for promoting actin polymerization [23–25]. In contrast, the EVH1 domain mediates intracellular targeting of Ena/VASP proteins by interacting with the “FPPPP” repeats of diverse proteins, including zyxin [26,27], and determines the recruitment of Ena/VASP proteins to specific sites within the cell [22]. The central proline-rich region harbors binding sites for SH3 and WW domain-containing proteins and the actin monomer-binding protein profilin [28]. Ena/VASP proteins are localized to the leading edge of lamellipodia and the tips of filopodia, but also to stress fibers and focal adhesions [28,29]. MENA is the only family member that contains a unique long insertion close to EVH1 domain of five-amino acid long stretch of highly charged basic and acidic amino acids (LERER) [28]. Notably, MENA binds to the C-terminal end of the cytoplasmic tail of the integrin  $\alpha 5$  via LERER domain, affecting  $\alpha 5\beta 1$  signaling [30]. Differently from all other members of Ena/VASP, there are multiple splice variants of the MENA gene, enabled homolog (*ENAH*), which are involved in several mechanisms critical for cancer progression. *ENAH* contains a small coding exon 11a that is included only in epithelial cells and excluded in mesenchymal cell lines and downregulated during epithelial-mesenchymal transition (EMT) [31–33]. The splicing of this exon is mainly regulated by the Epithelial Splicing Regulatory Proteins 1 and 2 (ESRP1 and ESRP2) [33]. In invasive tumor cells, the hMENA<sup>11a</sup> downregulation occurs, and the human MENA (hMENA) splice variant lacking the internal exon 6 (hMENA $\Delta$ v6) is upregulated [34]. *ENAH* splice variants containing alternative exons ++ and +++ (Mena INV), linked to cancer cell invasiveness, have also been described [35,36]. Our group has identified the two alternatively expressed isoforms, hMENA<sup>11a</sup> and hMENA $\Delta$ v6, that exert opposite roles in breast, lung, and pancreatic cancer cell invasiveness [34,37,38]. Their role during cancer progression and their crosstalk with TGF $\beta$  signaling will be discussed in Section 4 and Section 5.

### 2.3. Actin Dynamics and Signaling: From ECM to the Nucleus

Cell–matrix contacts are dynamic, and cells sense external force and make adjustments, by modulating the cytoskeleton filaments and their linkages to transmembrane proteins [39]. At sites of cell-ECM adhesion, cells sense physical features of the microenvironment through integrins and other adhesive proteins and adjust their own tensional state through actomyosin contractility and organization of the F-actin cytoskeleton to counterbalance extracellular forces [39,40]. Thus, the mechanotransduction process relies on force generation by actin-myosin networks and force transmission through adhesive complexes. Actomyosin contractility is the result of contractile force predominantly generated by the action of myosin II motors on actin filaments. The RhoA and RhoC family members promote actomyosin contractile force generation through ROCK1- and ROCK2-mediated

phosphorylation of different downstream target proteins, including LIM kinases 1 and 2 (LIMK1 and LIMK2), the myosin regulatory light chain (MLC) [41]. Force transmission at adhesive complexes relies on the activation of integrins which are clustered into macromolecular structures associated with plasma membrane at the cytoplasmic side, namely focal adhesions, that provide a direct physical link between intracellular actin cytoskeleton and ECM. Integrin activation results from a conformational reorganization of the  $\alpha$ - $\beta$  integrin dimer that critically increases its affinity to the matrix ligand. Proteins such as talins and kindlins bind to  $\beta$  integrin cytoplasmic domains, connecting them to the actin cytoskeleton [2]. A reciprocal regulation between integrins and F-actin exists: integrins promote bundling of actin filaments to generate tension within a cell. Conversely, actin regulatory proteins, actin polymerization, and spatial organization affect integrin function [39].

By playing a key part in the matrix-sensing machinery, actin cytoskeleton, for a long time considered the skeleton of the cell, now emerges as a platform for signal transduction [4], able to transmit tensile stresses generated at the interface between the cell and ECM to the nucleus, thus affecting nuclear properties and gene expression programs [42].

LINC (linker of nucleoskeleton and cytoskeleton) complex is one illustrative player of the transduction of mechanical signals to the nucleus through cytoskeletal physical links [43]. LINC complex, located at the nuclear envelope (NE), enables dynamic rearrangements of the cytoskeletal actin to be communicated to the nucleus. The nuclear membrane proteins Nesprins are components of the LINC complex and sustain the physical connection between the cytoskeleton and nuclear lamina, allowing cells to maintain tension between the plasma membrane and nucleus, essential for both organelle and cytoskeletal organization [44]. Nesprins are characterized by a C-terminal transmembrane domain, the KASH-domain, which anchors them in the nuclear membrane and a N-terminal domain by which they connect the nucleus to the actin cytoskeleton (Nesprin-1 and -2). Connections within the nucleus are mediated by nuclear lamina (lamins A, B1, B2, and C) and associated proteins like emerin.

To the actin cytoskeleton-mediated nuclear transduction also contribute transcription factors such as Yes-associated protein (YAP) and Myocardin-Related Transcription Factors (MRTFs), whose shuttling between the cytoplasm and the nucleus through the nuclear pore complex (NPC) is regulated by actin dynamics.

YAP and TAZ (transcriptional co-activator with PDZ-binding motif) are critical players in the sensing and transduction of mechanical cues to gene expression [45]. They elicit biological effects in response to ECM elasticity by acting as transcriptional cofactors that shuttle from the cytoplasm to the nucleus [45]. YAP and TAZ play key roles not only in physiological settings, but also in tumorigenesis, cancer stem cell induction, cancer-associated fibroblast (CAF) activation, and chemoresistance [46,47]. YAP/TAZ localize to the nucleus and are transcriptionally active in cells plated on large and stiff substrates, which display high ROCK-and non-muscle-myosin-II-driven cytoskeletal tension. Conversely, YAP/TAZ are excluded from the nucleus when cells are plated on softer or smaller substrates, which impose cell rounding and reduced adhesive area [48]. Noteworthy, YAP/TAZ activity is regulated by the conformation and tension of the F-actin cytoskeleton. Rather than F-actin total levels, YAP/TAZ is regulated by the F-actin subcellular organization, fine structure, tension, and resistance offered by molecular structures within the cytoskeleton and by the whole nucleus [48].

The MRTF-SRF circuit is activated by the Rho GTPase family, which regulates essentially every aspect of actin cytoskeleton function [49]. Rho GTPases actively participate in processes by which actin dynamics are transmitted up to the nucleus by regulating effector proteins that modulate the equilibrium of G-actin and F-actin in the cytoplasm. Actin polymerization, downstream to Rho GTPases thus affects the MRTF-SRF (serum response factor) circuit. In the presence of high levels of cytoplasmic G-actin, MRTFs, able to bind G-actin, are retained in the cytoplasm. Changes in actin dynamics may imply the incorporation of G-actin into the F-actin filaments, causing a reduction of G-actin concentration,

thus leaving MRTFs free to enter the nucleus and to interact with the transcription factor SRF, which drives the expression of its target genes [50].

It is important to mention that actin also exists within the nucleus, where it is involved in transcription, chromatin remodeling and intra-nuclear movements [51,52]. Although implicated in a variety of different nuclear processes, the underlying mechanisms still remain unclear.

### 3. TGF $\beta$ Biology and Signaling in Cancer

Herein, we briefly summarize basics of TGF $\beta$  biology and signaling that are covered more extensively in excellent reviews [53–57].

#### 3.1. Brief Overview of TGF $\beta$ Isoforms and Their Role in Normal and Pathological Context

Transforming growth factor  $\beta$  factors (TGF $\beta$ 1, TGF $\beta$ 2, and TGF $\beta$ 3) are multi-tasking cytokines implicated in the regulation of a broad range of cellular functions and different biological processes i.e., embryogenesis, immune regulation, fibrosis-associated diseases, and tumor progression [12,58].

Encoded by different genes and uniquely expressed in mammals [59], TGF $\beta$  isoforms exert peculiar and not-redundant functions in vivo, as suggested by the diversity of phenotypes of knockout mice for each isoform [60–63]. TGF $\beta$  ligands, alone or in the context of other environmental cues, balance the self-renewal and differentiation process of stem cells and define cell fate during embryonic lineage specification and differentiation [8]. A body of evidence has indicated TGF $\beta$  factors as crucial in controlling the immune system [64], during development and maturation of immune cells, in maintaining immune tolerance and homeostasis and controlling innate, as well as in the adaptive immune system [65–67]. Moreover, context-dependent pro- or anti-inflammatory effects have been clearly demonstrated [67].

Following tissue damage, TGF $\beta$ 1 becomes a master regulator of the repair process, providing a rapid restoration of tissue integrity, by reprogramming and suppressing excessive tissue inflammation [58,64,68–70].

The deregulation of TGF $\beta$  activity may shift the physiological repair to pathological condition such as fibrosis, an aberrant repair response which strongly affects organ functionality. TGF $\beta$  implication in the pathogenesis of fibrosis-associated diseases has been extensively sustained by experimental and in vivo models as well as clinical evidence [71–75]. On the other hand, therapeutic implementation of anti-TGF $\beta$  approaches in fibrosis-associated diseases is still hampered by the pleiotropic multifunctional role of TGF $\beta$ , leaving opened many questions to design effective therapies [58].

In cancer, TGF $\beta$  exerts both tumor-suppressive and tumor-promoting functions, referred to as “TGF $\beta$  Paradox”, which represents the most critical and cryptic issue of the physio-pathological TGF $\beta$  role [76,77]. To suppress tumor, TGF $\beta$  induces apoptosis in pre-malignant cells and inhibits cancer cell proliferation, whereas in the late stage of tumorigenesis, it sustains tumor progression. The switch from tumor-suppressive to tumor-promoting function of TGF $\beta$  is intimately linked to the triggering of EMT program, closely related to actin cytoskeleton modifications, as further detailed.

In the tumor microenvironment, stromal cells are an abundant source of TGF $\beta$  [78], with cancer-associated fibroblasts (CAFs) the most significant producers [79,80]. Activated TGF $\beta$  signaling leads to CAF activation, CAF-mediated cancer progression [81] and may differently influence CAF subsets [82].

Noteworthy, CAF-derived TGF $\beta$  may contribute to immunosurveillance and escape and may participate in therapy resistance, including immunotherapy with immune checkpoint blockade [83–85], also by excluding CD8+ T lymphocytes from the tumor site [86,87]. A recent paper suggests that TGF $\beta$  neutralization targets only selected CAF subtypes and, in turn, promotes CAF immunomodulatory properties and the formation of an immune-permissive tumor microenvironment (TME) by regulating ECM density [82].



### 3.2. Basics of TGF $\beta$ Signaling

TGF $\beta$  ligands signal to the nucleus, mainly through serine/threonine kinase receptors tetrameric complexes composed of two type II receptors (T $\beta$ RII) and two type I receptors (T $\beta$ RI). The receptor activation initiates signaling via both canonical SMAD2/3 and non-canonical pathways.

In the canonical TGF $\beta$ -SMAD pathway, upon TGF $\beta$  binding, T $\beta$ RII trans-phosphorylates T $\beta$ RI and activates its kinase activity resulting in phosphorylation and mobilization of SMAD proteins which include SMAD1, 2, 3, 5 and 8 [88]. SMAD2/3 phosphorylation is required for their association with SMAD4 in mammalian cells [89]. This heterotrimeric complex translocates into the nucleus where it activates or represses the transcription of several genes [88,90]. The interaction of SMAD protein complex with other transcription factors and/or with additional co-activators and co-repressors as well as with chromatin-modifying enzymes ensures the context-dependent cellular response to TGF $\beta$  signaling [57].

In the non-canonical pathways, TGF $\beta$  can activate the mitogen-activated protein kinases (MAPKs), the extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/AKT, TNF receptor-associated factor 4/6 (TRAF 4/6) and Rho-like GTPases (Rho) [56,91–95]. Notably, TGF $\beta$  has been reported as able to crosstalk with several other signaling pathways (i.e., Wnt, Notch, Hippo signaling, and with tyrosine kinase receptors) to elicit a context-dependent signaling [12,96].

### 4. TGF $\beta$ -Induced Actin Reorganization in Physio-and Pathological Contexts


The actin cytoskeleton reorganization is one of the earliest cellular response to TGF $\beta$  signaling, which may generate rapid and long-term modifications of actin dynamics, thus modulating morphology, adhesion, growth, motility, and invasiveness of different cell types. In both non-transformed and transformed epithelial cells, TGF $\beta$  can rapidly induce membrane ruffling and actin polymerization at the cell edges [97], whereas a prolonged stimulus results in stable actin filament bundles (stress fibers) [98]. In the short-term response, TGF $\beta$  induces rapid activation of GTPases Rho family, including Rac, Cell Division Cycle 42 (CDC42), and RhoA [98], followed by ROCK/LIMK/cofilin pathway activation and actin cytoskeleton polymerization [99]. On the contrary, the long-term actin cytoskeleton response involves the SMAD pathway, and leads to transcriptional regulation of RhoB and  $\alpha$ -SMA in fibroblasts [100].

TGF $\beta$  induces myofibroblast differentiation by increasing Rho-dependent cytoskeletal stress fiber formation and Rho/actin/MRTF-A/SRF signaling pathway [101].

TGF $\beta$  signaling controls cellular plasticity and is essential in EMT promotion, a physiological process crucial in tissue and organ formation during development, but also acts as a facilitator of tumor progression [102]. Remodeling of the cytoskeleton is a hallmark of EMT, and notably, the actin regulatory genes are the most highly upregulated during TGF $\beta$ -induced EMT [103–107]. Several actin cytoskeleton-associated proteins, including hMENA and hMENA $\Delta$ v6, have been reported to be upregulated during EMT [38,103–105,108,109]. Functionally, as a consequence of the TGF $\beta$ -induced cytoskeletal remodeling, actin stress fibers are formed in cancer cells, affecting cell shape and function and favoring cancer cell invasion and tissue rigidity [107].

### 5. Actin-Related Regulatory Functions that Control TGF $\beta$ Signaling

Whether TGF $\beta$  signaling affects actin cytoskeleton is well established, the reciprocal contribution of actin dynamics on TGF $\beta$  signaling regulation is still not enough explored. In this section, we will discuss the specific interactions of actin-related functions with TGF $\beta$  pathway, from ECM to the nucleus (Figure 1) passing through the receptor trafficking.



**Figure 1.** Schematic representation of transforming growth factor  $\beta$  (TGF $\beta$ ) signaling regulation by actin remodeling induced by extracellular matrix (ECM) stiffness. Activation of Rho GTPase by mechanical cues promotes F-actin assembly and actin cytoskeleton contractility, which activates TGF $\beta$  signaling by: (a) Inducing TGF $\beta$  ligand release and activation. The ECM-integrin-actin cytoskeleton linkages allow integrin to shift toward an active configuration that favors TGF $\beta$  release from LTBP/latent TGF $\beta$  complex. Active TGF $\beta$  initiates signaling via TGF $\beta$  receptors, which ultimately drives the phosphorylation-dependent formation of SMAD2/3-4 complex. This complex translocates to the nucleus and facilitates the transcription of TGF $\beta$ -dependent genes; (b) Accumulating at the front of the nucleus of the lamin-binding protein Nesprin-2, which induces SMAD nuclear localization; (c) Inhibiting the formation of both cytosolic and nuclear LEMD3-SMAD2/3 complexes, resulting in the relief of LEMD3 negative regulation; (d) Activating YAP/TAZ pathway, which regulates both SMAD2/3 shuttling and SMAD-dependent transcriptional activity; (e) Controlling myocardin-related transcription factor A (MRTF-A) localization to mediate the SMAD-dependent transcriptional activity.

### 5.1. TGF $\beta$ Ligand Activation: Mechanical Cues

Differently from most of the growth factors that are ready to function upon secretion, TGF $\beta$  is typically secreted and stored in the ECM as a latent non-active form. This includes a signal peptide (N-terminal latency-associated peptide LAP), and a C-terminal mature TGF $\beta$ , which corresponds to the mature active cytokine monomer [110,111]. The presence of LAP prevents binding of TGF $\beta$  to its receptors, impeding signaling function. After secretion, both LAP and mature TGF $\beta$ 1 homodimers are non-covalently associated in the small latent TGF $\beta$  complex (SLC). In most cases, LAP is further covalently associated in the ECM with a latent TGF $\beta$ -binding protein (LTBP), to create the large latent complex (LLC), an ECM reservoir of TGF $\beta$ . The activation of TGF $\beta$  requires the release of the LLC from the ECM and further proteolysis/deformation of LAP to release active TGF $\beta$  [13,112].

The best-understood mechanism of active TGF $\beta$  release from LLC involves the interaction with a specific subset of integrins, and several RGD-binding integrins are able to

activate latent TGF $\beta$  through binding to this site [113,114]. Contractile force generated by actin cytoskeleton is required for  $\alpha$ v $\beta$ 6 integrin-mediated activation of TGF $\beta$ 1 [115]. Tensile force is transmitted by cytoskeleton to integrins, which shift towards an active configuration that favors TGF $\beta$ 1 release [116]. The inhibitor of actin polymerization cytochalasin D abrogates  $\alpha$ v $\beta$ 6-mediated TGF $\beta$ 1 activation [115], whereas G-protein coupled receptor agonists induce  $\alpha$ v $\beta$ 6-mediated TGF $\beta$  activation. Downstream to G-protein coupled receptor agonists, RhoA and Rho kinase are activated, leading to cytoskeletal reorganization that generates cellular tension, which is transmitted to the cytoplasmic domains of the  $\alpha$ v $\beta$ 6 integrin, and, in turn, activates the large latent TGF $\beta$  complex [117–119].

TGF $\beta$  activation engages a dynamic reciprocity with ECM, and a stiffer ECM increases the free available TGF $\beta$  and its activation (Figure 1a), in turn driving a positive feedback by inducing matrix synthesis and stiffness, with pathological consequences [120]. Mechanistically, increased stiffness induces integrin clustering, and, in turn, the activation of Rho family GTPases, which stimulate actin remodeling. This integrin-actin linkage enables cell to sense ECM stiffness and regulates TGF $\beta$  signaling (Figure 1a) [40].

### 5.2. ECM-Driven SMAD Intracellular Localization and Transcriptional Activity

Noteworthy, the dynamic remodeling of the actin cytoskeleton is also involved in the localization and activation of SMADs (Figure 1b–e).

In the basal state, SMAD proteins constantly shuttle between the cytoplasm and the nucleus. Once phosphorylated by the receptors, nuclear SMADs activate or repress the transcription of several genes. The constant shuttle of SMAD proteins in to and out of the nucleus also relies on their interaction with the cytoskeleton. Below, some mechanisms of cytoskeleton-related SMAD shuttle are described.

The lamin-binding protein LEMD3 (MAN-1) inhibits TGF $\beta$  signaling by binding SMAD2/3 and promoting their dephosphorylation and nuclear export [121,122]. An interesting study by Chambers et al. has shown that the interaction of LEMD3 with SMAD2/3 is negatively regulated by ECM stiffness and antagonized by actin polymerization, highlighting that a stiffened ECM regulates cell response to TGF $\beta$  [123].

Nesprin-2 Giant isoform of the Nesprin family proteins is a component of the LINC complex at NE and participates to the mechanical force generation dependent on F-actin network rearrangements, by binding F-actin through the terminal actin-binding domain (ABD) [124]. Studies of wound healing in nesprin-2 Giant deficient mice have reported delayed wound closure and defects in keratinocyte and fibroblast migration and proliferation [125]. Notably, nesprin-2G deficient fibroblasts show defects in cytoskeleton, with F-actin filaments less regular around the nucleus, and a delayed nuclear SMAD accumulation upon TGF $\beta$  stimulation [125].

Actin-mediated mechanotransduction intercepts TGF $\beta$  signaling also via YAP/TAZ, effectors of the Hippo pathway, critically linked to actin cytoskeleton dynamics as discussed above. TAZ binds and retains SMAD complexes into the nucleus, coupling SMADs to transcriptional machinery. Cytoplasmic retention of phosphorylated TAZ prevents SMAD2/3-SMAD4 complex from accumulating in the nucleus, and TAZ knockdown leads to TGF $\beta$  signaling inhibition [126] (Figure 1d). An interesting study shows a multi-step mechanism integrating epithelial polarity with TGF $\beta$  signaling. In polarizing epithelial cells, Hippo pathway activation is an early event that promotes cytoplasmic sequestration of TAZ/YAP and suppression of TGF $\beta$ -SMAD activity, while prolonged stimulus leads to the basal-lateral restriction of TGF $\beta$  receptors, thus reducing SMAD activation. TGF $\beta$  receptor sequestration and YAP/TAZ cytoplasmic retention are distinct events that regulate TGF $\beta$  signaling in polarized epithelia [127].

Consistent with the involvement of actin cytoskeleton in cellular response to mechanical cues, several studies support a link between matrix rigidity, Rho-Actin-MRTF signatures and TGF $\beta$  pathway (Figure 1e). Although the details of this crosstalk are elusive, MRTFs, and in particular MRTF-A, are key regulators of cytoskeletal genes involved in matrix rigidity and TGF $\beta$ 1-induced EMT. Indeed, TGF $\beta$  induces the translocation of MRTFs in to



the nucleus and MRTF/SMAD3 complex activates *slug* transcription [128]. Noteworthy, MRTF-A is implicated in TGF $\beta$ 1-mediated myofibroblastic differentiation in various cell systems and CAF functions [129,130].

In addition, matrix stiffness regulates cytoskeletal architecture [131], and induces the nuclear localization of MRTF-A [132,133], required for the activation of colon and pulmonary fibroblasts [134,135]. The sum of these findings indicates that ECM stiffness and Actin-MRTF-A signaling are crucial in TGF $\beta$ 1-induced EMT.

### 5.3. Intracellular Trafficking of TGF $\beta$ Receptors

Different mechanisms regulating TGF $\beta$  receptor availability on the cell surface have been reported [136]. Membrane localization and trafficking of receptors are dynamically regulated by two distinct endocytic pathways: clathrin-dependent internalization into the early endosome, important for propagating signal through the SMAD-dependent pathway, and internalization in caveolin-1-positive lipid rafts that sequester TGF $\beta$  receptors for their degradation [137].


Actin dynamics, mainly by regulating intracellular vesicle transport, take part in the complex regulation of TGF $\beta$  receptor trafficking via numerous actin regulatory proteins (Figure 2).

Fascin actin-bundling protein 1 (FSCN1), a direct TGF $\beta$ /Nodal target gene, is specifically required for the trafficking of T $\beta$ RI from clathrin-coated vesicles to early endosomes, promoting TGF $\beta$  signaling. In particular, FSCN1 specifically interacts with T $\beta$ RI, and its depletion disrupts the association between receptors and actin filaments and sequesters the internalized receptors into clathrin-coated vesicles (Figure 2a) [138]. Notably, FSCN1 is upregulated by TGF $\beta$ /Nodal signaling also in a range of tumor cells and overexpressed in different carcinomas where correlates with the clinical aggressiveness [139], suggesting that FSCN1 sustains TGF $\beta$  signaling also during tumor progression.

The monomeric small GTPase Rab11 contributes to TGF $\beta$  receptor recycling occurring in early endosome compartments, a process that requires the actin-binding protein VASP. In an experimental liver metastasis mouse model, VASP, by regulating Rab11-dependent T $\beta$ RII recycling to the plasma membrane, sustains TGF $\beta$  signaling activation. Reciprocally, TGF $\beta$  stimulation results in VASP upregulation in hepatic stellate cells (HSCs). Overall, TGF $\beta$ -mediated activation of HSCs within the hepatic tumor microenvironment is a process essential for metastatic tumor growth in the liver, and VASP takes part to this process by sensitizing hepatic stellate cells to TGF $\beta$  effects [140] (Figure 2b).

Unconventional myosins, known to participate in the endocytic trafficking and tether membranes or transport them along the actin cytoskeleton, [141] have been linked to the regulation of TGF $\beta$  receptor trafficking. Their specific inhibition reduces cell surface expression of T $\beta$ RII and promotes receptor degradation (Figure 2c) [142].

T $\beta$ RII recycling is also affected by Arf GAP with GTP-binding protein-like domain, Ankyrin repeat, and PH domain 2 isoform 2 (AGAP2), a member of Arf GAP (ADP-ribosylation factor GTPase activating proteins) family, critical regulators of membrane trafficking and remodeling of actin cytoskeleton. In the pathophysiology of liver cancer, the depletion of AGAP2 inhibits the recycling of T $\beta$ RII back to the plasmatic membrane with an important implication in TGF $\beta$ -driven pro-fibrotic effects [143]. Proliferation and migration of HSC induced by TGF $\beta$  are reduced by AGAP2 depletion and loss of AGAP2 also interferes with TGF $\beta$ -dependent collagen type I production (Figure 2d).




**Figure 2.** Actin regulatory proteins controlling TGF $\beta$  type I receptors (T $\beta$ RI) and II trafficking. (a) The internalized T $\beta$ RI into clathrin-coated vesicles is linked to the actin cytoskeleton via fascin actin-bundling protein 1 (FSCN1) which promotes the trafficking of internalized receptors from clathrin-coated vesicles to early endosomes and thus TGF $\beta$  signaling. (b) VASP promotes TGF $\beta$  activity by sustaining the complex between Rab11 and T $\beta$ RII that favors T $\beta$ RII recycling to the plasma membrane. (c) Myosins sustain TGF $\beta$  signaling by sustaining the cell-surface expression of T $\beta$ RII receptor and inhibiting its degradation. (d) Arf GAP with GTP-binding protein-like domain, Ankyrin repeat, and PH domain 2 isoform 2 (AGAP2) sustains TGF $\beta$  signaling, by directly or indirectly interacting with T $\beta$ RII and sustaining the recycling of the receptor to the plasma membrane.

#### 5.4. SMAD-Dependent Transcriptional Activation

The dynamic of actin cytoskeleton also influences the expression of the negative regulators of TGF $\beta$  signaling, Ski (Sloan-Kettering Institute proto-oncogene) and SnoN (Ski-related novel gene) proteins [144]. Ski and SnoN are able to interact with SMAD2/3 and SMAD4 in the cytoplasm and to recruit elements of the repressor machinery on TGF $\beta$  target gene promoters [145–147]. Notably, the TGF $\beta$ /Smad pathway and co-regulators Ski and SnoN clearly control each other by activating positive and negative feedback mechanisms. Ski and SnoN are upregulated by TGF $\beta$  signaling and, in turn, they act in a negative feedback manner. Moreover, TGF $\beta$  regulates Ski and SnoN levels by inducing their degradation *via* the ubiquitin-proteasome system [148,149]. The alteration in these regulatory mechanisms controls the magnitude and duration of the TGF $\beta$  signal and may lead to disease development [150]. Remarkably, changes in actin cytoskeleton dynamics control Ski protein stability and subcellular localization induced by TGF $\beta$  in normal hepatocytes mechanisms suggested to be lost in hepatoma cells (Figure 3) [151]. Interestingly, while

the inhibition of actin-cytoskeleton rearrangements by cytochalasin D treatment induces a rapid and strong degradation of Ski protein, it stabilizes SnoN protein. This differential actin-cytoskeleton-mediated regulation of the two proteins controls different sets of TGF $\beta$  target genes, as demonstrated in normal hepatocytes. On the contrary, in hepatoma cells the actin-mediated modulation of Ski and SnoN protein stability is lost or deeply modified (Figure 3) [152].



**Figure 3.** Actin cytoskeleton dynamics control the expression levels of Ski and SnoN, negative regulators of TGF $\beta$  signaling. TGF $\beta$  signaling controls expression levels of the negative regulators Ski and SnoN, by inducing both their upregulation and their ubiquitin (Ub)-mediated degradation. In normal hepatocytes, actin cytoskeleton dynamics induce Ski protein degradation and SnoN protein stabilization, and might impact TGF $\beta$  signaling outcome. This mechanism is lost in hepatoma cells [151,152].

### 5.5. Actin-Dynamic Regulators that Control TGF $\beta$ Signaling

Several actin regulatory proteins affect TGF $\beta$  signaling at different levels. The roles of Rho GTPase family have been extensively described. Herein, we focus on the role of the actin cytoskeleton regulatory protein hMENA, which regulates TGF $\beta$  signaling. Of note, *ENAH* gene splicing is regulated by TGF $\beta$ . Furthermore, a number of other actin regulatory proteins are reported and summarized in Table 1.

**Table 1.** Actin regulatory proteins affecting TGF $\beta$  signaling.

Actin Regulatory Protein	Role in TGF $\beta$ Signaling	Function	References
<b>RhoA</b>	SMAD2/3 phosphorylation/activation	Modulates SMAD Signaling during TGF $\beta$ -induced Smooth Muscle Differentiation	[153]
<b>RhoB</b>	SMAD-mediated transcriptional activity	Antagonizes TGF $\beta$ transcriptional program	[154]
	Transcription of T $\beta$ RII	Antagonizes TGF $\beta$ -mediated anti-proliferative and transcriptional responses in keratinocytes and pancreatic carcinoma cells	[155]
<b>Rac1</b>	SMAD2 phosphorylation/activation	Antagonizes TGF $\beta$ 1-mediated growth inhibition and sustains TGF $\beta$ 1-induced cell migration in pancreatic ductal adenocarcinoma cells	[156]
<b>Rac1b</b>	SMAD2/3 phosphorylation/activation	Inhibits TGF $\beta$ 1-induced cell motility in pancreatic ductal epithelial cells	[157]
	Synthesis and secretion of TGF $\beta$ 1	Suppresses cell motility	[158]
	TGF $\beta$ 1-mediated p38MAPK and MEK-ERK activation	Antagonizes TGF $\beta$ 1-dependent EMT	[159]
<b>WAVE3</b>	Transcription of EMT-related genes	Regulates TGF $\beta$ -mediated EMT and growth and metastasis of triple-negative breast cancer cells	[160]
<b>hMENA/hMENA<math>\Delta</math>v6</b>	SMAD2/3 phosphorylation/activation	Regulates TGF $\beta$ -mediated EMT in PDAC cells	[38]
<b>Zyxin</b>	Regulation of TGF $\beta$ -induced integrin $\alpha$ 5 $\beta$ 1 expression	Regulates cancer cell motility and EMT during lung cancer development and progression	[161]
	Regulation of EMT-related protein	Mediates cooperation between Hippo and TGF $\beta$ signaling pathways	[162]
<b>Cofilin</b>		Drives Cell-Invasive and Metastatic Responses to TGF- $\beta$ in Prostate Cancer	[163]
	Regulation of EMT-related morphology and protein expression	Sustains TGF $\beta$ -mediated EMT in gastric cancer cells	[164]
		Sustains migration and invasion during EMT of CRC cells	[165]
<b>Filamin</b>	SMAD localization	Sustains SMAD-dependent TGF $\beta$ signaling	[166]
<b>Profilin 2</b>	Epigenetic regulation of SMAD2 and SMAD3	Promotes lung cancer growth and metastasis	[167]
<b>Formins</b>	SMAD-mediated transcriptional activity	Sustains TGF $\beta$ -mediated EMT	[168]

The Rho family of small GTPases, by controlling the polymerization and depolymerization of actin filaments, regulates specific actin cytoskeletal structures, including stress fibers, lamellipodia, and filopodia [49,169]. Rho proteins exert both a positive and negative regulatory role of SMAD-dependent TGF $\beta$  signaling. The complete inhibition of Rho activity by C3 exotoxin attenuated SMAD-mediated transactivation and the ectopic expression of a dominant-negative RhoA mutant in neural crest stem cells blocked SMAD2 and SMAD3 phosphorylation and their translocation to the nucleus [153]. On the other



hand, the overexpression of RhoB in epithelial cells has been shown to inhibit TGF $\beta$  transcriptional program [154]. RhoB but not RhoA overexpression in HaCaT keratinocytes and pancreatic carcinoma cells decreases the expression levels of T $\beta$ RII and antagonizes the TGF $\beta$ -mediated anti-proliferative responses.

Interestingly, antagonistic functions in the regulation of TGF $\beta$  signaling have also been reported for the two alternatively spliced isoforms of Rho, ras-related C3 botulinum toxin substrate 1 (RAC1), and RAC1b proteins. Most of the studies have shown a positive interaction between RAC1 and TGF $\beta$  signaling [170–172], since RAC1 can be activated by TGF $\beta$  and may promote the activation of SMAD2. Surprisingly, despite its high structural similarity with RAC1, RAC1b has been shown to be a negative regulator of SMAD signaling, acting as an endogenous inhibitor of RAC1. RAC1b maintains a differentiated epithelial phenotype and prevents the RAC1-driven EMT process [173,174] and cell migration [175]. RAC1b also antagonizes TGF $\beta$  dependent EMT by inhibiting p38 and MEK/ERK signaling. Recently, Ungefroren et al. have suggested that RAC1b confers anti-oncogenic properties to pancreatic carcinoma cells not only by acting as an antagonist of RAC1, but also by directly affecting the regulation of main components of TGF $\beta$  signal pathway [176]. Ungefroren et al. have also recently revealed an unexpected role of RAC1B in the regulation of TGF $\beta$  secretion implicated in cell motility suppression [158]. It is interesting to note that RAC1b increases malignant transformation in response to other EMT-inducers, such as MMP3 [177,178]. Noteworthy, the knockdown of the master regulator of EMT, ESRP1, but not ESRP2, increases the level of RAC1b in head and neck squamous cancer cells [179]. Considering that RAC1 and RAC1b control TGF $\beta$  responses in cancer cells in an antagonistic manner, the final outcome of TGF $\beta$  signal transduction, in a given tissue or cell type, appears to be strictly dependent on RAC1b/RAC1 ratio [176,180].

Downstream of the Rho GTPases, WAVE3, belonging to the WASP/WAVE family of proteins, activates the Arp2/3 complex, leading to actin polymerization and assembly of actin filaments [181], playing a critical role in cell motility and invasion [182]. WAVE3 expression is highly upregulated by TGF $\beta$  in metastatic triple-negative breast cancer cells (TNBCs), where is required for TGF $\beta$ -mediated EMT [160]. Noteworthy, the Authors suggest that the TGF $\beta$ -induced increase of WAVE3 expression correlates with the functional conversion of TGF $\beta$  from a suppressor to a promoter of TNBC development, proposing that therapeutic targeting of WAVE3 may restore the cytostatic activities of TGF $\beta$  in late-stage TNBCs [160]. hMENA and its isoforms critically support malignant transformation and progression in different tumors [37,38,183–186]. Our studies indicated that the alternative splicing of *ENAH* gene generates the alternatively expressed epithelial hMENA<sup>11a</sup> and mesenchymal hMENA $\Delta$ v6 isoforms, which contribute to isoform-specific actin cytoskeleton organization, crucial in activating signaling pathways related to immunosuppressive TME such as TGF $\beta$ ,  $\beta$ 1 integrin, and AXL-GAS6 signaling [38,186,187]. hMENA spliced variants have been linked to TGF $\beta$ -induced EMT process and TGF $\beta$  is involved in the regulation of splicing of *ENAH* gene. TGF $\beta$  inhibits the expression of the epithelial splicing factor epithelial splicing regulatory proteins 1/2 (ESRP1/2) and primes the switching of hMENA isoforms by excluding the exon 11a in mammary epithelial and breast cancer cells [33,34,188–190]. In addition, TGF $\beta$  induces the expression of polypyrimidine tract-binding protein 1 (PTBP1), involved in exon 11a skipping, enhancing migration and invasion of lung cancer cells as well as EMT features in A549 cells [191]. Interestingly, loss of CDC-like kinase 2 (CLK2), kinase linked to the splicing factor RBFOX2, has been shown to activate EMT and TGF $\beta$  signaling pathway [192]. Notably, our group has demonstrated that TGF $\beta$ 1 treatment downregulates hMENA<sup>11a</sup> expression in pancreatic cancer cell lines, which we have proposed as a prerequisite for EMT [38]. Differently, TGF $\beta$ 1 upregulates hMENA and the mesenchymal pro-invasive hMENA $\Delta$ v6 isoform, implicated in SMAD2 phosphorylation and TGF $\beta$ 1-induced EMT [38]. Noteworthy, hMENA/hMENA $\Delta$ v6 overexpression defines a CAF subtype with pro-tumoral functions and hMENA expression in CAFs is able to regulate both autocrine and paracrine TGF $\beta$  signaling, leading to the regulation of TGF $\beta$ -mediated crosstalk between CAFs and tumor cells (unpublished data).

We also demonstrated that hMENA isoforms interact with ECM/ $\beta$ 1 integrin axis by modulating the expression and activation of  $\beta$ 1 integrin and the composition of ECM. Indeed, depletion of all hMENA isoforms in lung cancer cells results in abrogation of stress fibers, actin reorganization, and a dramatic cell shape change, affecting the balance between actin polymerization and depolymerization, that results in F-actin decrease. As a consequence, hMENA affects MRTF-A subcellular localization, SRF activity, and in turn the expression of its target gene  $\beta$ 1 integrin.

From a clinical point of view, the pattern of hMENA isoform expression associates with clinical outcome in pancreatic and lung cancer patients [37,38,193].

We have demonstrated that in tumor tissues of early NSCLC patients, the presence of the epithelial-associated isoform, hMENA<sup>11a</sup> is associated with a low expression of fibronectin in the stroma, and that these tumor features identify patients with better prognosis [186].

The actin regulatory protein Zyxin directly interacts with-actinin and Ena/VASP proteins to dock them to actin filaments [194,195]. Zyxin primarily localizes to focal adhesion, where serves as a docking protein involved in the regulation of cell-extracellular matrix adhesion and in the mechano-transduction process [196]. Several studies pointed at a significant role of zyxin in both physiological and pathological TGF $\beta$ 1-mediated EMT. In a context of pathological EMT, zyxin has been shown to be not only a functional target of TGF $\beta$ , but also an effector of the TGF $\beta$  signaling regulation. Indeed, in lung cancer cells, it controls cell motility through the modulation of cell adhesion and expression of integrin  $\alpha$ 5 $\beta$ 1 [161]. Zyxin-knockdown in MDA-MB-231 breast cancer cells abrogates the TGF $\beta$ -mediated E-cadherin downregulation and impairs TGF $\beta$ -induced cell motility, supporting the notion that zyxin controls TGF $\beta$ -induced migration [162]. Recently, high zyxin expression has been associated with a poor prognosis in glioblastoma multiforme patients [197].

A tight association between actin cytoskeleton dynamics and TGF $\beta$ 1-induced EMT program has also been evidenced for cofilin-1 activity, crucial for the regulation of cell migration and invasion [198]. Cofilin is directly involved in the actin polymerization and remodeling dynamics in response to extracellular signals, including TGF $\beta$  and has been firstly identified as a SMAD-independent intracellular effector of TGF $\beta$  signaling in prostate cancer cells [199]. Collazo et al. found that Cofilin1 activity coordinates the responses to TGF $\beta$  needed for cancer cell migration and metastasis in murine and human prostate cancer [163]. In gastric cancer cells, Wang et al., proved the role of Cofilin in actin-mediated TGF $\beta$ -induced EMT [164]. In addition, in colorectal cancer (CRC) Cofilin-1 has been shown to augment the cell-cell disassembly, migration, invasion, and focal adhesion organization during TGF $\beta$ -induced EMT. Interestingly, in urothelial cancer, Hensley et al., found a close association of high nuclear localization of Cofilin-1 with increased tumor stage and progression, and have suggested that Cofilin-1 involvement in EMT may be due to its ability to control gene expression by regulating actin organization in the nucleus [200].

Filamin has been identified as a SMAD-binding protein, and Filamin-deficient melanoma cells showed an impaired SMAD2 phosphorylation [166]. Its role as a scaffold to connect the actin cytoskeleton with a multitude of proteins involved in signal transduction has been extensively reported [201–204]. Due to its ability to interact with SMAD proteins, Filamin has been proposed to function as an anchor protein able to control SMAD protein localization near the cell surface receptors or to keep SMAD conformation, allowing T $\beta$ RI-mediated phosphorylation [166]. Although Filamin has been originally identified as a tumor promoting factor, prognostic value is mainly dependent on its subcellular localization and binding with different proteins [205]. High Filamin levels have been shown to be predictors of poor patient outcome in several tumors including melanoma, breast, and glioblastoma multiforme [206]. Whereas, the Filamin A isoform has been shown to inhibit tumor progression by regulating breast cancer type 1 susceptibility protein (BRCA1) expression in human breast cancer [207].

An interesting role for actin-binding proteins in the epigenetic regulation of TGF $\beta$  signaling has been shown for Profilin 2 (Pfn2). It prevents nuclear translocation of HDAC1 and suppresses its recruitment to SMAD2 and SMAD3 promoters, thus leading to transcriptional activation of SMAD2 and SMAD3. Moreover, Pfn2 correlates with SMAD3 expression in human lung cancers, where its overexpression promotes lung cancer growth and metastasis [167]. On the other hand, the loss of profilin 2 contributes to enhanced EMT and metastasis of colorectal cancer. Thus, the prognostic value of Pfn2 is still controversial [208,209].

Among actin regulatory proteins which nucleate the assembly of unbranched actin filaments, the Formins and in particular the two Formin family members, diaphanous-related formin 1 and 3 (DIAPH1 and DIAPH3) have a crucial role in TGF $\beta$ -induced EMT in several tumor cells (i.e., lung, mammary, and renal epithelial cells) [168,210]. The inhibition of Formins, and not of Arp2/3 complex, completely blocked both TGF $\beta$ -mediated cell transcription and morphological changes as suggested by their ability to increase the activity of SRF [211,212].

## 6. Conclusions and Perspectives

Herein, we highlight how actin dynamics and TGF $\beta$  signaling act in tissue homeostasis and how their deregulation leads to fibrosis and cancer. Key proteins involved in the actin cytoskeleton described in this review are linked to TGF $\beta$  signaling and TGF $\beta$ -mediated EMT. Our effort was to envision how the deregulation of pathways from ECM to the nucleus involves actin dynamics, contributing to TGF $\beta$ -mediated cancer progression. While substantial insights in the field were obtained, new layers of complexity and regulation continue to be discovered.

For progress to occur in the understanding of the crucial role of actin dynamics in cancer, a significant effort needs to be made to identify master regulators of TGF $\beta$  pro-tumor activity mediated by actin cytoskeleton dynamics. The comprehension of these mechanisms during cancer progression and overall in therapy resistance will be a future cornerstone for novel TGF $\beta$ -directed therapies in the new era of immuno-oncology.

**Author Contributions:** R.M. and P.T. designed and drafted the manuscript; A.T. prepared the figures; P.N. designed and revised the manuscript and critically discussed the content. All authors have read and agreed to the published version of the manuscript.

**Funding:** The work of P.N. laboratory is supported by the Italian Association for Cancer Research AIRC: 5  $\times$  1000, 12182 (P.N.) and IG 19822 (P.N.).

**Acknowledgments:** The Authors thank all components of the Laboratory for their support and in particular Francesca Di Modugno for her critical comments and suggestions. The Authors apologize to those authors whose important studies have not been cited due to space limitations. Figures were created with BioRender (<http://biorender.com/>, accessed on 22 February 2021).

**Conflicts of Interest:** The Authors declare no conflict of interest.

## References

1. Davidson, A.J.; Wood, W. Unravelling the Actin Cytoskeleton: A New Competitive Edge? *Trends Cell Biol.* **2016**, *26*, 569–576. [[CrossRef](#)]
2. Geiger, B.; Spatz, J.P.; Bershadsky, A.D. Environmental sensing through focal adhesions. *Nat. Rev. Mol. Cell Biol.* **2009**, *10*, 21–33. [[CrossRef](#)]
3. Moujaber, O.; Stochaj, U. The Cytoskeleton as Regulator of Cell Signaling Pathways. *Trends Biochem. Sci.* **2020**, *45*, 96–107. [[CrossRef](#)]
4. Olson, E.N.; Nordheim, A. Linking actin dynamics and gene transcription to drive cellular motile functions. *Nat. Rev. Mol. Cell Biol.* **2010**, *11*, 353–365. [[CrossRef](#)] [[PubMed](#)]
5. Thomas, B.J.; Kan, O.K.; Loveland, K.L.; Elias, J.A.; Bardin, P.G. In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-beta. *Am. J. Respir. Cell Mol. Biol.* **2016**, *55*, 759–766. [[CrossRef](#)] [[PubMed](#)]
6. Benke, K.; Ágg, B.; Szilveszter, B.; Tarr, F.; Nagy, Z.B.; Pólos, M.; Daróczy, L.; Merkely, B.; Szabolcs, Z. The role of transforming growth factor-beta in Marfan syndrome. *Cardiol. J.* **2013**, *20*, 227–234. [[CrossRef](#)]

7. Shovlin, C.L. Molecular Defects in Rare Bleeding Disorders: Hereditary Haemorrhagic Telangiectasia. *Thromb. Haemost.* **1997**, *78*, 145–150. [[CrossRef](#)] [[PubMed](#)]
8. Mullen, A.C.; Wrana, J.L. TGF-beta Family Signaling in Embryonic and Somatic Stem-Cell Renewal and Differentiation. *Cold Spring Harb. Perspect. Biol.* **2017**, *9*, a022186. [[CrossRef](#)] [[PubMed](#)]
9. Beyer, T.A.; Narimatsu, M.; Weiss, A.; David, L.; Wrana, J.L. The TGFbeta superfamily in stem cell biology and early mammalian embryonic development. *Biochim. Biophys. Acta* **2013**, *1830*, 2268–2279. [[CrossRef](#)]
10. Morikawa, M.; Derynck, R.; Miyazono, K. TGF-beta and the TGF-beta Family: Context-Dependent Roles in Cell and Tissue Physiology. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a021873. [[CrossRef](#)]
11. Chen, W.; Ten Dijke, P. Immunoregulation by members of the TGFbeta superfamily. *Nat. Rev. Immunol.* **2016**, *16*, 723–740. [[CrossRef](#)] [[PubMed](#)]
12. David, C.J.; Massague, J. Contextual determinants of TGFbeta action in development, immunity and cancer. *Nat. Rev. Mol. Cell Biol.* **2018**, *19*, 419–435. [[CrossRef](#)]
13. Hinz, B. The extracellular matrix and transforming growth factor-beta1: Tale of a strained relationship. *Matrix Biol.* **2015**, *47*, 54–65. [[CrossRef](#)] [[PubMed](#)]
14. Pollard, T.D. Actin and Actin-Binding Proteins. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a018226. [[CrossRef](#)] [[PubMed](#)]
15. Blanchoin, L.; Boujemaa-Paterski, R.; Sykes, C.; Plastino, J. Actin Dynamics, Architecture, and Mechanics in Cell Motility. *Physiol. Rev.* **2014**, *94*, 235–263. [[CrossRef](#)]
16. Campellone, K.G.; Welch, M.D. A nucleator arms race: Cellular control of actin assembly. *Nat. Rev. Mol. Cell Biol.* **2010**, *11*, 237–251. [[CrossRef](#)] [[PubMed](#)]
17. Mockrin, S.C.; Korn, E.D. Acanthamoeba profilin interacts with G-actin to increase the rate of exchange of actin-bound adenosine 5'-triphosphate. *Biochemistry* **1980**, *19*, 5359–5362. [[CrossRef](#)]
18. Edwards, M.; Zwolak, A.; Schafer, D.A.; Sept, D.; Dominguez, R.; Cooper, J.A. Capping protein regulators fine-tune actin assembly dynamics. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 677–689. [[CrossRef](#)]
19. Svitkina, T. The Actin Cytoskeleton and Actin-Based Motility. *Cold Spring Harb. Perspect. Biol.* **2018**, *10*, a018267. [[CrossRef](#)] [[PubMed](#)]
20. Matsudaira, P. Actin crosslinking proteins at the leading edge. *Semin. Cell Biol.* **1994**, *5*, 165–174. [[CrossRef](#)] [[PubMed](#)]
21. Bear, J.E.; Gertler, F.B. Ena/VASP: Towards resolving a pointed controversy at the barbed end. *J. Cell Sci.* **2009**, *122 Pt 12*, 1947–1953. [[CrossRef](#)]
22. Krause, M.; Dent, E.W.; Bear, J.E.; Loureiro, J.J.; Gertler, F.B. Ena/VASP Proteins: Regulators of the Actin Cytoskeleton and Cell Migration. *Annu. Rev. Cell Dev. Biol.* **2003**, *19*, 541–564. [[CrossRef](#)] [[PubMed](#)]
23. Barzik, M.; Kotova, T.I.; Higgs, H.N.; Hazelwood, L.; Hanein, D.; Gertler, F.B.; Schafer, D.A. Ena/VASP Proteins Enhance Actin Polymerization in the Presence of Barbed End Capping Proteins. *J. Biol. Chem.* **2005**, *280*, 28653–28662. [[CrossRef](#)] [[PubMed](#)]
24. Breitsprecher, D.; Kiesewetter, A.K.; Linkner, J.; Urbanke, C.; Resch, G.P.; Small, J.V.; Faix, J. Clustering of VASP actively drives processive, WH2 domain-mediated actin filament elongation. *EMBO J.* **2008**, *27*, 2943–2954. [[CrossRef](#)] [[PubMed](#)]
25. Breitsprecher, D.; Kiesewetter, A.K.; Linkner, J.; Vinzenz, M.; Stradal, T.E.B.; Small, J.V.; Curth, U.; Dickinson, R.B.; Faix, J. Molecular mechanism of Ena/VASP-mediated actin-filament elongation. *EMBO J.* **2011**, *30*, 456–467. [[CrossRef](#)] [[PubMed](#)]
26. Niebuhr, K.; Ebel, F.; Frank, R.; Reinhard, M.; Domann, E.; Carl, U.D.; Walter, U.; Gertler, F.B.; Wehland, J.; Chakraborty, T. A novel proline-rich motif present in ActA of *Listeria monocytogenes* and cytoskeletal proteins is the ligand for the EVH1 domain, a protein module present in the Ena/VASP family. *EMBO J.* **1997**, *16*, 5433–5444. [[CrossRef](#)] [[PubMed](#)]
27. Bear, J.E.; Loureiro, J.J.; Libova, I.; Fässler, R.; Wehland, J.; Gertler, F.B. Negative Regulation of Fibroblast Motility by Ena/VASP Proteins. *Cell* **2000**, *101*, 717–728. [[CrossRef](#)]
28. Gertler, F.B.; Niebuhr, K.; Reinhard, M.; Wehland, J.; Soriano, P. Mena, a Relative of VASP and *Drosophila Enabled*, Is Implicated in the Control of Microfilament Dynamics. *Cell* **1996**, *87*, 227–239. [[CrossRef](#)]
29. Reinhard, M.; Halbrugge, M.; Scheer, U.; Wiegand, C.; Jockusch, B.M.; Walter, U. The 46/50 kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts. *EMBO J.* **1992**, *11*, 2063–2070. [[CrossRef](#)]
30. Gupton, S.L.; Riquelme, D.; Hughes-Alford, S.K.; Tadros, J.; Rudina, S.S.; Hynes, R.O.; Lauffenburger, D.; Gertler, F.B. Mena binds alpha5 integrin directly and modulates alpha5beta1 function. *J. Cell Biol.* **2012**, *198*, 657–676. [[CrossRef](#)]
31. Di Modugno, F.; DeMonte, L.; Balsamo, M.; Bronzi, G.; Nicotra, M.R.; Alessio, M.; Jager, E.; Condeelis, J.S.; Santoni, A.; Natali, P.G.; et al. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: Epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. *Cancer Res.* **2007**, *67*, 2657–2665. [[CrossRef](#)] [[PubMed](#)]
32. Pino, M.S.; Balsamo, M.; Di Modugno, F.; Mottolese, M.; Alessio, M.; Melucci, E.; Milella, M.; McConkey, D.J.; Philippar, U.; Gertler, F.B.; et al. Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. *Clin. Cancer Res.* **2008**, *14*, 4943–4950. [[CrossRef](#)]
33. Warzecha, C.C.; Jiang, P.; Amirikian, K.; Dittmar, K.A.; Lu, H.; Shen, S.; Guo, W.; Xing, Y.; Carstens, R.P. An ESRP-regulated splicing programme is abrogated during the epithelial–mesenchymal transition. *EMBO J.* **2010**, *29*, 3286–3300. [[CrossRef](#)] [[PubMed](#)]



34. Di Modugno, F.; Iapicca, P.; Boudreau, A.; Mottolese, M.; Terrenato, I.; Perracchio, L.; Carstens, R.P.; Santoni, A.; Bissell, M.J.; Nisticò, P. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 19280–19285. [[CrossRef](#)] [[PubMed](#)]
35. Goswami, S.; Philippar, U.; Sun, D.; Patsialou, A.; Avraham, J.; Wang, W.; Di Modugno, F.; Nistico, P.; Gertler, F.B.; Condeelis, J.S. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. *Clin. Exp. Metastasis* **2009**, *26*, 153–159. [[CrossRef](#)]
36. Philippar, U.; Roussos, E.T.; Oser, M.; Yamaguchi, H.; Kim, H.-D.; Giampieri, S.; Wang, Y.; Goswami, S.; Wyckoff, J.B.; Lauffenburger, D.A.; et al. A Mena Invasion Isoform Potentiates EGF-Induced Carcinoma Cell Invasion and Metastasis. *Dev. Cell* **2008**, *15*, 813–828. [[CrossRef](#)]
37. Bria, E.; Di Modugno, F.; Sperduti, I.; Iapicca, P.; Visca, P.; Alessandrini, G.; Antoniani, B.; Pilotto, S.; Ludovini, V.; Vannucci, J.; et al. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. *Oncotarget* **2014**, *5*, 11054–11063. [[CrossRef](#)] [[PubMed](#)]
38. Melchionna, R.; Iapicca, P.; Di Modugno, F.; Trono, P.; Sperduti, I.; Fassan, M.; Cataldo, I.; Rusev, B.C.; Lawlor, R.T.; Diodoro, M.G.; et al. The pattern of hMENA isoforms is regulated by TGF-beta1 in pancreatic cancer and may predict patient outcome. *Oncoimmunology* **2016**, *5*, e1221556. [[CrossRef](#)]
39. Vogel, V.; Sheetz, M.P. Local force and geometry sensing regulate cell functions. *Nat. Rev. Mol. Cell Biol.* **2006**, *7*, 265–275. [[CrossRef](#)]
40. Dufort, C.C.; Paszek, M.J.; Weaver, V.M. Balancing forces: Architectural control of mechanotransduction. *Nat. Rev. Mol. Cell Biol.* **2011**, *12*, 308–319. [[CrossRef](#)] [[PubMed](#)]
41. Amano, M.; Nakayama, M.; Kaibuchi, K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. *Cytoskeleton* **2010**, *67*, 545–554. [[CrossRef](#)] [[PubMed](#)]
42. Alisafaei, F.; Jokhun, D.S.; Shivashankar, G.V.; Shenoy, V.B. Regulation of nuclear architecture, mechanics, and nucleocytoplasmic shuttling of epigenetic factors by cell geometric constraints. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 13200–13209. [[CrossRef](#)] [[PubMed](#)]
43. Cho, S.; Irianto, J.; Discher, D.E. Mechanosensing by the nucleus: From pathways to scaling relationships. *J. Cell Biol.* **2017**, *216*, 305–315. [[CrossRef](#)] [[PubMed](#)]
44. Mellad, J.A.; Warren, D.T.; Shanahan, C.M. Nesprins LINC the nucleus and cytoskeleton. *Curr. Opin. Cell Biol.* **2011**, *23*, 47–54. [[CrossRef](#)]
45. Halder, G.; Dupont, S.; Piccolo, S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 591–600. [[CrossRef](#)] [[PubMed](#)]
46. Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP/TAZ at the Roots of Cancer. *Cancer Cell* **2016**, *29*, 783–803. [[CrossRef](#)]
47. Calvo, F.; Ege, N.; Grande-Garcia, A.; Hooper, S.; Jenkins, R.P.; Chaudhry, S.I.; Harrington, K.; Williamson, P.; Moeendarbary, E.; Charras, G.; et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nat. Cell Biol.* **2013**, *15*, 637–646. [[CrossRef](#)] [[PubMed](#)]
48. Totaro, A.; Panciera, T.; Piccolo, S. YAP/TAZ upstream signals and downstream responses. *Nat. Cell Biol.* **2018**, *20*, 888–899. [[CrossRef](#)]
49. Hall, A. Rho GTPases and the Actin Cytoskeleton. *Science* **1998**, *279*, 509–514. [[CrossRef](#)]
50. Posern, G.; Treisman, R. Actin' together: Serum response factor, its cofactors and the link to signal transduction. *Trends Cell Biol.* **2006**, *16*, 588–596. [[CrossRef](#)]
51. Serebryanny, L.; de Lanerolle, P. Nuclear actin: The new normal. *Mutat. Res.* **2020**, *821*, 111714. [[CrossRef](#)]
52. Spencer, V.A.; Costes, S.; Inman, J.L.; Xu, R.; Chen, J.; Hendzel, M.J.; Bissell, M.J. Depletion of nuclear actin is a key mediator of quiescence in epithelial cells. *J. Cell Sci.* **2010**, *124*, 123–132. [[CrossRef](#)]
53. Padua, D.; Massague, J. Roles of TGFbeta in metastasis. *Cell Res.* **2009**, *19*, 89–102. [[CrossRef](#)] [[PubMed](#)]
54. Neuzillet, C.; Tijeras-Raballand, A.; Cohen, R.; Cros, J.; Faivre, S.; Raymond, E.; de Gramont, A. Targeting the TGFbeta pathway for cancer therapy. *Pharmacol. Ther.* **2015**, *147*, 22–31. [[CrossRef](#)] [[PubMed](#)]
55. Kretzschmar, M.; Massague, J. SMADs: Mediators and regulators of TGF-beta signaling. *Curr. Opin. Genet. Dev.* **1998**, *8*, 103–111. [[CrossRef](#)]
56. Moustakas, A.; Heldin, C.H. The regulation of TGFbeta signal transduction. *Development* **2009**, *136*, 3699–3714. [[CrossRef](#)]
57. Derynck, R.; Budi, E.H. Specificity, versatility, and control of TGF-beta family signaling. *Sci. Signal.* **2019**, *12*, eaav5183. [[CrossRef](#)]
58. Frangogiannis, N. Transforming growth factor-beta in tissue fibrosis. *J. Exp. Med.* **2020**, *217*, e20190103. [[CrossRef](#)] [[PubMed](#)]
59. Hinck, A.P.; Mueller, T.D.; Springer, T.A. Structural Biology and Evolution of the TGF-beta Family. *Cold Spring Harb. Perspect Biol.* **2016**, *8*, a022103. [[CrossRef](#)] [[PubMed](#)]
60. Shull, M.M.; Ormsby, I.; Kier, A.B.; Pawlowski, S.; Diebold, R.J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D.; et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. *Nature* **1992**, *359*, 693–699. [[CrossRef](#)] [[PubMed](#)]
61. Dickson, M.C.; Martin, J.S.; Cousins, F.M.; Kulkarni, A.B.; Karlsson, S.; Akhurst, R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. *Development* **1995**, *121*, 1845–1854.
62. Proetzel, G.; Pawlowski, S.A.; Wiles, M.V.; Yin, M.; Boivin, G.P.; Howles, P.N.; Ding, J.; Ferguson, M.W.; Doetschman, T. Transforming growth factor-beta 3 is required for secondary palate fusion. *Nat. Genet.* **1995**, *11*, 409–414. [[CrossRef](#)]

63. Kulkarni, A.B.; Thyagarajan, T.; Letterio, J.J. Function of cytokines within the TGF-beta superfamily as determined from transgenic and gene knockout studies in mice. *Curr. Mol. Med.* **2002**, *2*, 303–327. [[CrossRef](#)] [[PubMed](#)]
64. Travis, M.A.; Sheppard, D. TGF-beta activation and function in immunity. *Annu. Rev. Immunol.* **2014**, *32*, 51–82. [[CrossRef](#)] [[PubMed](#)]
65. Flavell, R.A.; Sanjabi, S.; Wrzesinski, S.H.; Licona-Limón, P. The polarization of immune cells in the tumour environment by TGFbeta. *Nat. Rev. Immunol.* **2010**, *10*, 554–567. [[CrossRef](#)] [[PubMed](#)]
66. Sanjabi, S.; Oh, S.A.; Li, M.O. Regulation of the Immune Response by TGF-beta: From Conception to Autoimmunity and Infection. *Cold Spring Harb. Perspect Biol.* **2017**, *9*, a022236. [[CrossRef](#)] [[PubMed](#)]
67. Batlle, E.; Massague, J. Transforming Growth Factor-beta Signaling in Immunity and Cancer. *Immunity* **2019**, *50*, 924–940. [[CrossRef](#)]
68. Bartram, U.; Speer, C.P. The role of transforming growth factor beta in lung development and disease. *Chest* **2004**, *125*, 754–765. [[CrossRef](#)] [[PubMed](#)]
69. Bowen, T.; Jenkins, R.H.; Fraser, D.J. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. *J. Pathol.* **2012**, *229*, 274–285. [[CrossRef](#)]
70. Igotz, R.A.; Kelly, B.; Davis, R.J.; Massagué, J. Biologically active precursor for transforming growth factor type alpha, released by retrovirally transformed cells. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 6307–6311. [[CrossRef](#)]
71. Sime, P.J.; Xing, Z.; Graham, F.L.; Csaky, K.G.; Gaudie, J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. *J. Clin. Investig.* **1997**, *100*, 768–776. [[CrossRef](#)] [[PubMed](#)]
72. Sonnylal, S.; Denton, C.P.; Zheng, B.; Keene, D.R.; He, R.; Adams, H.P.; VanPelt, C.S.; Geng, Y.J.; Deng, J.M.; Behringer, R.R.; et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. *Arthritis Rheum.* **2007**, *56*, 334–344. [[CrossRef](#)]
73. Sanderson, N.; Factor, V.; Nagy, P.; Kopp, J.; Kondaiah, P.; Wakefield, L.; Roberts, A.B.; Sporn, M.B.; Thorgeirsson, S.S. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 2572–2576. [[CrossRef](#)]
74. Anscher, M.S.; Peters, W.P.; Reisenbichler, H.; Petros, W.P.; Jirtle, R.L. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. *N. Engl. J. Med.* **1993**, *328*, 1592–1598. [[CrossRef](#)] [[PubMed](#)]
75. Rice, L.M.; Padilla, C.M.; McLaughlin, S.R.; Mathes, A.L.; Ziemek, J.; Goummih, S.; Nakerakanti, S.; York, M.; Farina, G.; Whitfield, M.L.; et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. *J. Clin. Investig.* **2015**, *125*, 2795–2807. [[CrossRef](#)] [[PubMed](#)]
76. Tian, M.; Schiemann, W.P. The TGF-beta paradox in human cancer: An update. *Future Oncol.* **2009**, *5*, 259–271. [[CrossRef](#)] [[PubMed](#)]
77. Jakowlew, S.B. Transforming growth factor-beta in cancer and metastasis. *Cancer Metastasis Rev.* **2006**, *25*, 435–457. [[CrossRef](#)]
78. Massague, J. TGFbeta in Cancer. *Cell* **2008**, *134*, 215–230. [[CrossRef](#)]
79. Calon, A.; Espinet, E.; Palomo-Ponce, S.; Tauriello, D.V.; Iglesias, M.; Céspedes, M.V.; Sevillano, M.; Nadal, C.; Jung, P.; Zhang, X.H.F.; et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. *Cancer Cell.* **2012**, *22*, 571–584. [[CrossRef](#)]
80. Calon, A.; Lonardo, E.; Berenguer-Llgero, A.; Espinet, E.; Hernando-Momblona, X.; Iglesias, M.; Sevillano, M.; Palomo-Ponce, S.; Tauriello, D.V.F.; Byrom, D.; et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. *Nat. Genet.* **2015**, *47*, 320–329. [[CrossRef](#)]
81. Calon, A.; Tauriello, D.; Batlle, E. TGF-beta in CAF-mediated tumor growth and metastasis. *Semin. Cancer Biol.* **2014**, *25*, 15–22. [[CrossRef](#)]
82. Grauel, A.L.; Nguyen, B.; Ruddy, D.; Laszewski, T.; Schwartz, S.; Chang, J.; Chen, J.; Piquet, M.; Pelletier, M.; Yan, Z.; et al. TGFbeta-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. *Nat. Commun.* **2020**, *11*, 6315. [[CrossRef](#)]
83. Nakazawa, N.; Yokobori, T.; Kaira, K.; Turtoi, A.; Baatar, S.; Gombodorj, N.; Handa, T.; Tsukagoshi, M.; Ubukata, Y.; Kimura, A.; et al. High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. *Ann. Surg. Oncol.* **2019**, *27*, 933–942. [[CrossRef](#)] [[PubMed](#)]
84. Vanpouille-Box, C.; Formenti, S.C. Dual Transforming Growth Factor-beta and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors? *Trends Immunol.* **2018**, *39*, 435–437. [[CrossRef](#)]
85. Endo, E.; Okayama, H.; Nakajima, S.; Saito, K.; Nakano, H.; Endo, E.; Kase, K.; Ito, M.; Yamauchi, N.; Yamada, L.; et al. A TGFbeta-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer. *Mol. Cancer Res.* **2020**, *18*, 1402–1413. [[CrossRef](#)]
86. Tauriello, D.V.F.; Palomo-Ponce, S.; Stork, D.; Berenguer-Llgero, A.; Badia-Ramentol, J.; Iglesias, M.; Sevillano, M.; Ibiza, S.; Cañellas, A.; Hernando-Momblona, X.; et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* **2018**, *554*, 538–543. [[CrossRef](#)] [[PubMed](#)]
87. Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E., III; Koepfen, H.; Astarita, J.L.; Cubas, R.; et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* **2018**, *554*, 544–548. [[CrossRef](#)] [[PubMed](#)]

88. Massague, J. TGF-beta signal transduction. *Annu. Rev. Biochem.* **1998**, *67*, 753–791. [[CrossRef](#)] [[PubMed](#)]
89. Abdollah, S.; Macias-Silva, M.; Tsukazaki, T.; Hayashi, H.; Attisano, L.; Wrana, J.L. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. *J. Biol. Chem.* **1997**, *272*, 27678–27685. [[CrossRef](#)] [[PubMed](#)]
90. Feng, X.H.; Derynck, R. Specificity and versatility in tgf-beta signaling through Smads. *Annu. Rev. Cell. Dev. Biol.* **2005**, *21*, 659–693. [[CrossRef](#)]
91. Sorrentino, A.; Thakur, N.; Grimsby, S.; Marcusson, A.; Von Bulow, V.; Schuster, N.; Zhang, S.; Heldin, C.H.; Landström, M. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. *Nat. Cell Biol.* **2008**, *10*, 1199–1207. [[CrossRef](#)] [[PubMed](#)]
92. Heldin, C.H.; Moustakas, A. Signaling Receptors for TGF-beta Family Members. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a022053. [[CrossRef](#)]
93. Massague, J. TGFbeta signalling in context. *Nat. Rev. Mol. Cell. Biol.* **2012**, *13*, 616–630. [[CrossRef](#)]
94. Zhang, Y.E. Mechanistic insight into contextual TGF-beta signaling. *Curr. Opin. Cell. Biol.* **2018**, *51*, 1–7. [[CrossRef](#)]
95. Zhang, Y.E. Non-Smad pathways in TGF-beta signaling. *Cell Res.* **2009**, *19*, 128–139. [[CrossRef](#)] [[PubMed](#)]
96. Patel, S.; Tang, J.; Overstreet, J.M.; Anorga, S.; Lian, F.; Arnouk, A.; Goldschmeding, R.; Higgins, P.J.; Samarakoon, R. Rac-GTPase promotes fibrotic TGF-beta1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. *FASEB J.* **2019**, *33*, 9797–9810. [[CrossRef](#)]
97. Moustakas, A.; Stournaras, C. Regulation of actin organisation by TGF-beta in H-ras-transformed fibroblasts. *J. Cell Sci.* **1999**, *112*, 1169–1179.
98. Edlund, S.; Landstrom, M.; Heldin, C.H.; Aspenstrom, P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. *Mol. Biol. Cell.* **2002**, *13*, 902–914. [[CrossRef](#)]
99. Vardouli, L.; Moustakas, A.; Stournaras, C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. *J. Biol. Chem.* **2005**, *280*, 11448–11457. [[CrossRef](#)] [[PubMed](#)]
100. Vardouli, L.; Vasilaki, E.; Papadimitriou, E.; Kardassis, D.; Stournaras, C. A novel mechanism of TGFbeta-induced actin reorganization mediated by Smad proteins and Rho GTPases. *FEBS J.* **2008**, *275*, 4074–4087. [[CrossRef](#)]
101. Sandbo, N.; Dulin, N. Actin cytoskeleton in myofibroblast differentiation: Ultrastructure defining form and driving function. *Transl. Res.* **2011**, *158*, 181–196. [[CrossRef](#)] [[PubMed](#)]
102. Kahata, K.; Dadras, M.S.; Moustakas, A. TGF-beta Family Signaling in Epithelial Differentiation and Epithelial-Mesenchymal Transition. *Cold Spring Harb. Perspect. Biol.* **2018**, *10*, a022194. [[CrossRef](#)]
103. Zavadil, J.; Bitzer, M.; Liang, D.; Yang, Y.C.; Massimi, A.; Kneitz, S.; Piek, E.; Böttinger, E.P. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 6686–6691. [[CrossRef](#)]
104. Xie, L.; Law, B.K.; Aakre, M.E.; Edgerton, M.; Shyr, Y.; Bhowmick, N.A.; Moses, H.L. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. *Breast Cancer Res.* **2003**, *5*, R187–R198. [[CrossRef](#)] [[PubMed](#)]
105. Valcourt, U.; Kowanz, M.; Niimi, H.; Heldin, C.H.; Moustakas, A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. *Mol. Biol. Cell.* **2005**, *16*, 1987–2002. [[CrossRef](#)]
106. Keshamouni, V.G.; Michailidis, G.; Grasso, C.S.; Anthwal, S.; Strahler, J.R.; Walker, A.; Arenberg, D.A.; Reddy, R.C.; Akulapalli, S.; Thannickal, V.J.; et al. Differential Protein Expression Profiling by iTRAQ–2DLC–MS/MS of Lung Cancer Cells Undergoing Epithelial-Mesenchymal Transition Reveals a Migratory/Invasive Phenotype. *J. Proteome Res.* **2006**, *5*, 1143–1154. [[CrossRef](#)]
107. Gladilin, E.; Ohse, S.; Boerries, M.; Busch, H.; Xu, C.; Schneider, M.; Meister, M.; Eils, R. TGFbeta-induced cytoskeletal remodeling mediates elevation of cell stiffness and invasiveness in NSCLC. *Sci. Rep.* **2019**, *9*, 7667. [[CrossRef](#)] [[PubMed](#)]
108. Haynes, J.; Srivastava, J.; Madson, N.; Wittmann, T.; Barber, D.L. Dynamic actin remodeling during epithelial–mesenchymal transition depends on increased moesin expression. *Mol. Biol. Cell* **2011**, *22*, 4750–4764. [[CrossRef](#)] [[PubMed](#)]
109. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial–mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 178–196. [[CrossRef](#)] [[PubMed](#)]
110. Munger, J.S.; Harpel, J.G.; Gleizes, P.E.; Mazzieri, R.; Nunes, I.; Rifkin, D.B. Latent transforming growth factor-beta: Structural features and mechanisms of activation. *Kidney Int.* **1997**, *51*, 1376–1382. [[CrossRef](#)]
111. Barcellos-Hoff, M.H. Latency and activation in the control of TGF-beta. *J. Mammary Gland. Biol. Neoplasia* **1996**, *1*, 353–363. [[CrossRef](#)] [[PubMed](#)]
112. Robertson, I.B.; Rifkin, D.B. Regulation of the Bioavailability of TGF-beta and TGF-beta-Related Proteins. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a021907. [[CrossRef](#)] [[PubMed](#)]
113. Annes, J.P.; Chen, Y.; Munger, J.S.; Rifkin, D.B. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. *J. Cell Biol.* **2004**, *165*, 723–734. [[CrossRef](#)] [[PubMed](#)]
114. Munger, J.S.; Sheppard, D. Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. *Cold Spring Harb. Perspect. Biol.* **2011**, *3*, a005017. [[CrossRef](#)]
115. Munger, J.S.; Huang, X.; Kawakatsu, H.; Griffiths, M.J.; Dalton, S.L.; Wu, J.; Pittet, J.F.; Kaminski, N.; Garat, C.; Matthay, M.A.; et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. *Cell* **1999**, *96*, 319–328. [[CrossRef](#)]
116. Lodyga, M.; Hinz, B. TGF-beta1—A truly transforming growth factor in fibrosis and immunity. *Semin. Cell Dev. Biol.* **2020**, *101*, 123–139. [[CrossRef](#)] [[PubMed](#)]



117. Jenkins, R.G.; Su, X.; Su, G.; Scotton, C.J.; Camerer, E.; Laurent, G.J.; Davis, G.E.; Chambers, R.C.; Matthay, M.A.; Sheppard, D. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. *J. Clin. Invest.* **2006**, *116*, 1606–1614. [[CrossRef](#)] [[PubMed](#)]
118. Xu, M.Y.; Porte, J.; Knox, A.J.; Weinreb, P.H.; Maher, T.M.; Violette, S.M.; McAnulty, R.J.; Sheppard, D.; Jenkins, G. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). *Am. J. Pathol.* **2009**, *174*, 1264–1279. [[CrossRef](#)]
119. Tatler, A.L.; Jenkins, G. TGF-beta activation and lung fibrosis. *Proc. Am. Thorac. Soc.* **2012**, *9*, 130–136. [[CrossRef](#)]
120. Wipff, P.J.; Rifkin, D.B.; Meister, J.J.; Hinz, B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. *J. Cell. Biol.* **2007**, *179*, 1311–1323. [[CrossRef](#)]
121. Lin, F.; Morrison, J.M.; Wu, W.; Worman, H.J. MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling. *Hum. Mol. Genet.* **2005**, *14*, 437–445. [[CrossRef](#)] [[PubMed](#)]
122. Bourgeois, B.; Gilquin, B.; Tellier-Lebègue, C.; Östlund, C.; Wu, W.; Pérez, J.; El Hage, P.; Lallemand, F.; Worman, H.J.; Zinn-Justin, S. Inhibition of TGF-beta signaling at the nuclear envelope: Characterization of interactions between MAN1, Smad2 and Smad3, and PPM1A. *Sci. Signal.* **2013**, *6*, ra49. [[CrossRef](#)] [[PubMed](#)]
123. Chambers, D.M.; Moretti, L.; Zhang, J.J.; Cooper, S.W.; Chambers, D.M.; Santangelo, P.J.; Barker, T.H. LEM domain-containing protein 3 antagonizes TGFbeta-SMAD2/3 signaling in a stiffness-dependent manner in both the nucleus and cytosol. *J. Biol. Chem.* **2018**, *293*, 15867–15886. [[CrossRef](#)]
124. Zhen, Y.-Y.; Libotte, T.; Munck, M.; Noegel, A.A.; Korenbaum, E. NUANCE, a giant protein connecting the nucleus and actin cytoskeleton. *J. Cell Sci.* **2002**, *115*, 3207–3222.
125. Rashmi, R.; Eckes, B.; Eichinger, L.; Noegel, A.A.; Glöckner, G.; Groth, M.; Neumann, S.; Gloy, J.; Sellin, L.; Walz, G.; et al. The nuclear envelope protein Nesprin-2 has roles in cell proliferation and differentiation during wound healing. *Nucleus* **2012**, *3*, 172–186. [[CrossRef](#)] [[PubMed](#)]
126. Varelas, X.; Sakuma, R.; Samavarchi-Tehrani, P.; Peerani, R.; Rao, B.M.; Dembowy, J.; Yaffe, M.B.; Zandstra, P.W.; Wrana, J.L. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. *Nat. Cell Biol.* **2008**, *10*, 837–848. [[CrossRef](#)] [[PubMed](#)]
127. Narimatsu, M.; Samavarchi-Tehrani, P.; Varelas, X.; Wrana, J.L. Distinct polarity cues direct Taz/Yap and TGFbeta receptor localization to differentially control TGFbeta-induced Smad signaling. *Dev. Cell.* **2015**, *32*, 652–656. [[CrossRef](#)]
128. Morita, T.; Mayanagi, T.; Sobue, K. Dual roles of myocardin-related transcription factors in epithelial-mesenchymal transition via slug induction and actin remodeling. *J. Cell Biol.* **2007**, *179*, 1027–1042. [[CrossRef](#)]
129. Crider, B.J.; Risinger, G.M., Jr.; Haaksma, C.J.; Howard, E.W.; Tomasek, J.J. Myocardin-related transcription factors A and B are key regulators of TGF-beta1-induced fibroblast to myofibroblast differentiation. *J. Invest. Dermatol.* **2011**, *131*, 2378–2385. [[CrossRef](#)]
130. Werner, S.; Lützkendorf, J.; Müller, T.; Müller, L.P.; Posern, G. MRTF-A controls myofibroblastic differentiation of human multipotent stromal cells and their tumour-supporting function in xenograft models. *Sci. Rep.* **2019**, *9*, 11725. [[CrossRef](#)]
131. Yeung, T.; Georges, P.C.; Flanagan, L.A.; Marg, B.; Ortiz, M.; Funaki, M.; Zahir, N.; Ming, W.; Weaver, V.; Janmey, P.A. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. *Cell Motil. Cytoskelet.* **2004**, *60*, 24–34. [[CrossRef](#)] [[PubMed](#)]
132. Gomez, E.W.; Chen, Q.K.; Gjorevski, N.; Nelson, C.M. Tissue geometry patterns epithelial-mesenchymal transition via intercellular mechanotransduction. *J. Cell. Biochem.* **2010**, *110*, 44–51. [[CrossRef](#)] [[PubMed](#)]
133. Gjorevski, N.; Boghaert, E.; Nelson, C.M. Regulation of Epithelial-Mesenchymal Transition by Transmission of Mechanical Stress through Epithelial Tissues. *Cancer Microenviron.* **2011**, *5*, 29–38. [[CrossRef](#)] [[PubMed](#)]
134. Huang, X.; Yang, N.; Fiore, V.F.; Barker, T.H.; Sun, Y.; Morris, S.W.; Ding, Q.; Thannickal, V.J.; Zhou, Y. Matrix Stiffness-Induced Myofibroblast Differentiation Is Mediated by Intrinsic Mechanotransduction. *Am. J. Respir. Cell Mol. Biol.* **2012**, *47*, 340–348. [[CrossRef](#)] [[PubMed](#)]
135. Johnson, L.A.; Rodansky, E.S.; Haak, A.J.; Larsen, S.D.; Neubig, R.R.; Higgins, P.D. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. *Inflamm. Bowel. Dis.* **2014**, *20*, 154–165. [[CrossRef](#)] [[PubMed](#)]
136. Yakymovych, I.; Yakymovych, M.; Heldin, C.H. Intracellular trafficking of transforming growth factor beta receptors. *Acta Biochim. Biophys. Sin.* **2018**, *50*, 3–11. [[CrossRef](#)] [[PubMed](#)]
137. Di Guglielmo, G.M.; Le Roy, C.; Goodfellow, A.F.; Wrana, J.L. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. *Nat. Cell Biol.* **2003**, *5*, 410–421. [[CrossRef](#)]
138. Liu, Z.; Ning, G.; Xu, R.; Cao, Y.; Meng, A.; Wang, Q. Fscn1 is required for the trafficking of TGF-beta family type I receptors during endoderm formation. *Nat. Commun.* **2016**, *7*, 12603. [[CrossRef](#)] [[PubMed](#)]
139. Hashimoto, Y.; Kim, D.J.; Adams, J.C. The roles of fascin in health and disease. *J. Pathol.* **2011**, *224*, 289–300. [[CrossRef](#)] [[PubMed](#)]
140. Tu, K.; Li, J.; Shah, V.H.; Kang, N.; Verma, V.K.; Liu, C.; Billadeau, D.D.; Lamprecht, G.; Xiang, X.; Guo, L.; et al. Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors. *Hepatology* **2014**, *61*, 361–374. [[CrossRef](#)]
141. Batters, C.; Veigel, C. Mechanics and Activation of Unconventional Myosins. *Traffic* **2016**, *17*, 860–871. [[CrossRef](#)]



142. Shih-Wei, W.; Chih-Ling, C.; Kao, Y.C.; Martin, R.; Knölker, H.J.; Shiao, M.S.; Chen, C.L. Pentabromopseudilin: A myosin V inhibitor suppresses TGF-beta activity by recruiting the type II TGF-beta receptor to lysosomal degradation. *J. Enzyme Inhib. Med. Chem.* **2018**, *33*, 920–935. [[CrossRef](#)] [[PubMed](#)]
143. Navarro-Corcuera, A.; Ansorena, E.; Montiel-Duarte, C.; Iraburu, M.J. AGAP2: Modulating TGFbeta1-Signaling in the Regulation of Liver Fibrosis. *Int. J. Mol. Sci.* **2020**, *21*, 1400. [[CrossRef](#)]
144. Deheuninck, J.; Luo, K. Ski and SnoN, potent negative regulators of TGF-beta signaling. *Cell Res.* **2009**, *19*, 47–57. [[CrossRef](#)] [[PubMed](#)]
145. Tabata, T.; Kokura, K.; Ten Dijke, P.; Ishii, S. Ski co-repressor complexes maintain the basal repressed state of the TGF-beta target gene, SMAD7, via HDAC3 and PRMT. *Genes Cells* **2009**, *14*, 17–28. [[CrossRef](#)] [[PubMed](#)]
146. Denissova, N.G.; Liu, F. Repression of Endogenous Smad7 by Ski. *J. Biol. Chem.* **2004**, *279*, 28143–28148. [[CrossRef](#)] [[PubMed](#)]
147. Tecalco-Cruz, A.C.; Sosa-Garrocho, M.; Vázquez-Victorio, G.; Ortiz-García, L.; Domínguez-Hüttinger, E.; Macías-Silva, M. Transforming growth factor-beta/SMAD Target gene SKIL is negatively regulated by the transcriptional cofactor complex SNON-SMAD. *J. Biol. Chem.* **2012**, *287*, 26764–26776. [[CrossRef](#)]
148. Imamura, T.; Oshima, Y.; Hikita, A. Regulation of TGF-beta family signalling by ubiquitination and deubiquitination. *J. Biochem.* **2013**, *154*, 481–489. [[CrossRef](#)]
149. Sun, Y.; Liu, X.; Ng-Eaton, E.; Lodish, H.F.; Weinberg, R.A. SnoN and Ski protooncogenes are rapidly degraded in response to transforming growth factor beta signaling. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 12442–12447. [[CrossRef](#)] [[PubMed](#)]
150. Tecalco-Cruz, A.C.; Rios-Lopez, D.G.; Vázquez-Victorio, G.; Rosales-Alvarez, R.E.; Macias-Silva, M. Transcriptional cofactors Ski and SnoN are major regulators of the TGF-beta/Smad signaling pathway in health and disease. *Signal. Transduct. Target. Ther.* **2018**, *3*, 15. [[CrossRef](#)] [[PubMed](#)]
151. Vázquez-Victorio, G.; Caligaris, C.; Del Valle-Espinosa, E.; Sosa-Garrocho, M.; González-Arenas, N.R.; Reyes-Cruz, G.; Briones-Orta, M.A.; Macías-Silva, M. Novel Regulation of Ski Protein Stability and Endosomal Sorting by Actin Cytoskeleton Dynamics in Hepatocytes. *J. Biol. Chem.* **2015**, *290*, 4487–4499. [[CrossRef](#)] [[PubMed](#)]
152. Caligaris, C.; Vázquez-Victorio, G.; Sosa-Garrocho, M.; Ríos-López, D.G.; Marín-Hernández, A.; Macías-Silva, M. Actin-cytoskeleton polymerization differentially controls the stability of Ski and SnoN co-repressors in normal but not in transformed hepatocytes. *Biochim. Biophys. Acta BBA Gen. Subj.* **2015**, *1850*, 1832–1841. [[CrossRef](#)]
153. Chen, S.; Crawford, M.; Day, R.M.; Briones, V.R.; Leader, J.E.; Jose, P.A.; Lechleider, R.J. RhoA modulates Smad signaling during transforming growth factor-beta-induced smooth muscle differentiation. *J. Biol. Chem.* **2006**, *281*, 1765–1770. [[CrossRef](#)]
154. Engel, M.E.; Datta, P.K.; Moses, H.L. RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation. *J. Biol. Chem.* **1998**, *273*, 9921–9926. [[CrossRef](#)] [[PubMed](#)]
155. Adnane, J.; Seijo, E.; Chen, Z.; Bizouarn, F.; Leal, M.; Sebtí, S.M.; Muñoz-Antonia, T. RhoB, not RhoA, represses the transcription of the transforming growth factor beta type II receptor by a mechanism involving activator protein. *J. Biol. Chem.* **2002**, *277*, 8500–8507. [[CrossRef](#)] [[PubMed](#)]
156. Ungefroren, H.; Groth, S.; Sebens, S.; Lehnert, H.; Gieseler, F.; Fändrich, F. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: Control by Rac. *Mol. Cancer.* **2011**, *10*, 67. [[CrossRef](#)] [[PubMed](#)]
157. Ungefroren, H.; Sebens, S.; Giehl, K.; Helm, O.; Groth, S.; Fändrich, F.; Röcken, C.; Sipos, B.; Lehnert, H.; Gieseler, F. Rac1b negatively regulates TGF-beta1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling. *Oncotarget* **2014**, *5*, 277–290. [[CrossRef](#)]
158. Ungefroren, H.; Otterbein, H.; Wellner, U.F.; Keck, T.; Lehnert, H.; Marquardt, J.U. RAC1B Regulation of TGFB1 Reveals an Unexpected Role of Autocrine TGFbeta1 in the Suppression of Cell Motility. *Cancers* **2020**, *12*, 3570. [[CrossRef](#)]
159. Witte, D.; Otterbein, H.; Förster, M.; Giehl, K.; Zeiser, R.; Lehnert, H.; Ungefroren, H. Negative regulation of TGF-beta1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b. *Sci. Rep.* **2017**, *7*, 17313. [[CrossRef](#)]
160. Taylor, M.A.; Davuluri, G.; Parvani, J.G.; Schiemann, B.J.; Wendt, M.K.; Plow, E.F.; Schiemann, W.P.; Sossey-Alaoui, K. Upregulated WAVE3 expression is essential for TGF-beta-mediated EMT and metastasis of triple-negative breast cancer cells. *Breast Cancer Res. Treat.* **2013**, *142*, 341–353. [[CrossRef](#)] [[PubMed](#)]
161. Mise, N.; Savai, R.; Yu, H.; Schwarz, J.; Kaminski, N.; Eickelberg, O. Zyxin Is a Transforming Growth Factor-beta (TGF-beta)/Smad3 Target Gene That Regulates Lung Cancer Cell Motility via Integrin alpha5beta1. *J. Biol. Chem.* **2012**, *287*, 31393–31405. [[CrossRef](#)]
162. Ma, B.; Cheng, H.; Gao, R.; Mu, C.; Chen, L.; Wu, S.; Chen, Q.; Zhu, Y. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-beta signalling pathways. *Nat. Commun.* **2016**, *7*, 11123. [[CrossRef](#)]
163. Collazo, J.; Zhu, B.; Larkin, S.; Martin, S.K.; Pu, H.; Horbinski, C.; Koochekpour, S.; Kyprianou, N. Cofilin drives cell-invasive and metastatic responses to TGF-beta in prostate cancer. *Cancer Res.* **2014**, *74*, 2362–2373. [[CrossRef](#)]
164. Wang, H.; Tao, L.; Jin, F.; Gu, H.; Dai, X.; Ni, T.; Feng, J.; Ding, Y.; Xiao, W.; Qian, Y.; et al. Cofilin 1 induces the epithelial-mesenchymal transition of gastric cancer cells by promoting cytoskeletal rearrangement. *Oncotarget* **2017**, *8*, 39131–39142. [[CrossRef](#)] [[PubMed](#)]
165. Sousa-Squiavinato, A.C.M.; Rocha, M.R.; Barcellos-de-Souza, P.; de Souza, W.F.; Morgado-Diaz, J.A. Cofilin-1 signaling mediates epithelial-mesenchymal transition by promoting actin cytoskeleton reorganization and cell-cell adhesion regulation in colorectal cancer cells. *Biochim. Biophys. Acta Mol. Cell. Res.* **2019**, *1866*, 418–429. [[CrossRef](#)] [[PubMed](#)]

166. Sasaki, A.; Masuda, Y.; Ohta, Y.; Ikeda, K.; Watanabe, K. Filamin associates with Smads and regulates transforming growth factor-beta signaling. *J. Biol. Chem.* **2001**, *276*, 17871–17877. [[CrossRef](#)]
167. Tang, Y.-N.; Ding, W.-Q.; Guo, X.-J.; Yuan, X.-W.; Wang, D.-M.; Song, J.-G. Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. *Nat. Commun.* **2015**, *6*, 8230. [[CrossRef](#)] [[PubMed](#)]
168. Rana, M.K.; Aloisio, F.M.; Choi, C.; Barber, D.L. Formin-dependent TGF-beta signaling for epithelial to mesenchymal transition. *Mol. Biol. Cell.* **2018**, *29*, 1465–1475. [[CrossRef](#)]
169. Lawson, C.D.; Ridley, A.J. Rho GTPase signaling complexes in cell migration and invasion. *J. Cell Biol.* **2018**, *217*, 447–457. [[CrossRef](#)]
170. Santibanez, J.F.; Kocic, J.; Fabra, A.; Cano, A.; Quintanilla, M. Rac1 modulates TGF-beta1-mediated epithelial cell plasticity and MMP9 production in transformed keratinocytes. *FEBS Lett.* **2010**, *584*, 2305–2310. [[CrossRef](#)]
171. Wang, S.E.; Yu, Y.; Criswell, T.L.; DeBusk, L.M.; Lin, P.C.; Zent, R.; Johnson, D.H.; Ren, X.; Arteaga, C.L. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. *Oncogene* **2010**, *29*, 3335–3348. [[CrossRef](#)]
172. Shen, H.-J.; Sun, Y.-H.; Zhang, S.-J.; Jiang, J.-X.; Dong, X.-W.; Jia, Y.-L.; Shen, J.; Guan, Y.; Zhang, L.-H.; Li, F.-F.; et al. Cigarette smoke-induced alveolar epithelial–mesenchymal transition is mediated by Rac1 activation. *Biochim. Biophys. Acta* **2014**, *1840*, 1838–1849. [[CrossRef](#)]
173. Zinn, R.; Otterbein, H.; Lehnert, H.; Ungefroren, H. RAC1B: A Guardian of the Epithelial Phenotype and Protector Against Epithelial-Mesenchymal Transition. *Cells* **2019**, *8*, 1569. [[CrossRef](#)] [[PubMed](#)]
174. Ungefroren, H.; Otterbein, H.; Fiedler, C.; Mihara, K.; Hollenberg, M.D.; Gieseler, F.; Lehnert, H.; Witte, D. RAC1B Suppresses TGF- $\beta$ 1-Dependent Cell Migration in Pancreatic Carcinoma Cells through Inhibition of the TGF- $\beta$  Type I Receptor ALK. *Cancers* **2019**, *11*, 691. [[CrossRef](#)]
175. Otterbein, H.; Lehnert, H.; Ungefroren, H. Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan. *Cancers* **2019**, *11*, 1959. [[CrossRef](#)]
176. Ungefroren, H.; Wellner, U.F.; Keck, T.; Lehnert, H.; Marquardt, J.-U. The Small GTPase RAC1B: A Potent Negative Regulator of-and Useful Tool to Study-TGF $\beta$  Signaling. *Cancers* **2020**, *12*, 3475. [[CrossRef](#)] [[PubMed](#)]
177. Radisky, D.C.; Levy, D.D.; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A.; et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. *Nat. Cell Biol.* **2005**, *436*, 123–127. [[CrossRef](#)]
178. Stallings-Mann, M.L.; Waldmann, J.; Zhang, Y.; Miller, E.; Gauthier, M.L.; Visscher, D.W.; Downey, G.P.; Radisky, E.S.; Fields, A.P.; Radisky, D.C. Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression. *Sci. Transl. Med.* **2012**, *4*, 142ra95. [[CrossRef](#)]
179. Ishii, H.; Saitoh, M.; Sakamoto, K.; Kondo, T.; Katoh, R.; Tanaka, S.; Motizuki, M.; Masuyama, K.; Miyazawa, K. Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) Suppress Cancer Cell Motility via Different Mechanisms. *J. Biol. Chem.* **2014**, *289*, 27386–27399. [[CrossRef](#)] [[PubMed](#)]
180. Melzer, C.; Hass, R.; von der Ohe, J.; Lehnert, H.; Ungefroren, H. The role of TGF-beta and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma. *Cell Commun. Signal.* **2017**, *15*, 19. [[CrossRef](#)]
181. Takenawa, T.; Suetsugu, S. The WASP-WAVE protein network: Connecting the membrane to the cytoskeleton. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 37–48. [[CrossRef](#)]
182. Martin, T.A.; Frugtniet, B.; Jiang, W.G. Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis. *Breast Cancer: Targets Ther.* **2015**, *7*, 99–109. [[CrossRef](#)]
183. Gertler, F.; Condeelis, J. Metastasis: Tumor cells becoming MENAcing. *Trends Cell Biol.* **2011**, *21*, 81–90. [[CrossRef](#)]
184. Di Modugno, F.; Mottolese, M.; Di Benedetto, A.; Conidi, A.; Novelli, F.; Perracchio, L.; Venturo, I.; Botti, C.; Jager, E.; Santoni, A.; et al. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. *Clin. Cancer Res.* **2006**, *12*, 1470–1478. [[CrossRef](#)] [[PubMed](#)]
185. Wang, D.-D.; Jin, Q.; Wang, L.-L.; Han, S.-F.; Chen, Y.-B.; Sun, G.-D.; Sun, S.-F.; Sun, S.-W.; Wang, T.; Liu, F.-J.; et al. The significance of ENAH in carcinogenesis and prognosis in gastric cancer. *Oncotarget* **2017**, *8*, 72466–72479. [[CrossRef](#)] [[PubMed](#)]
186. Di Modugno, F.; Spada, S.; Palermo, B.; Visca, P.; Iapicca, P.; Di Carlo, A.; Antoniani, B.; Sperduti, I.; Di Benedetto, A.; Terrenato, I.; et al. hMENA isoforms impact NSCLC patient outcome through fibronectin/beta1 integrin axis. *Oncogene* **2018**, *37*, 5605–5617. [[CrossRef](#)]
187. Melchionna, R.; Spada, S.; Di Modugno, F.; D’Andrea, D.; Di Carlo, A.; Panetta, M.; Mileo, A.M.; Sperduti, I.; Antoniani, B.; Gallo, E.; et al. The actin modulator hMENA regulates GAS 6- AXL axis and pro-tumor cancer/stromal cell cooperation. *EMBO Rep.* **2020**, *21*, e50078. [[CrossRef](#)]
188. Horiguchi, K.; Sakamoto, K.; Koinuma, D.; Semba, K.; Inoue, A.; Inoue, S.; Fujii, H.; Yamaguchi, A.; Miyazawa, K.; Miyazono, K.; et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. *Oncogene* **2012**, *31*, 3190–3201. [[CrossRef](#)]
189. Saitoh, M.; Miyazawa, K. Transcriptional and post-transcriptional regulation in TGF-beta-mediated epithelial-mesenchymal transition. *J. Biochem.* **2012**, *151*, 563–571. [[CrossRef](#)]

190. Ahuja, N.; Ashok, C.; Natua, S.; Pant, D.; Cherian, A.; Pandkar, M.R.; Yadav, P.; Narayanan, S.S.V.; Mishra, J.; Samaiya, A.; et al. Hypoxia-induced TGF-beta-RBFOX2-ESRP1 axis regulates human MENA alternative splicing and promotes EMT in breast cancer. *NAR Cancer*. **2020**, *2*, zcaa021. [[CrossRef](#)] [[PubMed](#)]
191. Li, S.; Shen, L.; Huang, L.; Lei, S.; Cai, X.; Breitzig, M.; Zhang, B.; Yang, A.; Ji, W.; Huang, M.; et al. PTBP1 enhances exon11a skipping in Mena pre-mRNA to promote migration and invasion in lung carcinoma cells. *Biochim. Biophys. Acta Gene. Regul. Mech.* **2019**, *1862*, 858–869. [[CrossRef](#)]
192. Yoshida, T.; Kim, J.H.; Carver, K.; Su, Y.; Weremowicz, S.; Mulvey, L.; Yamamoto, S.; Brennan, C.; Mei, S.; Long, H.; et al. CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. *Cancer Res.* **2015**, *75*, 1516–1526. [[CrossRef](#)]
193. Di Modugno, F.; Caprara, V.; Chellini, L.; Tocci, P.; Spadaro, F.; Ferrandina, G.; Sacconi, A.; Blandino, G.; Nisticò, P.; Bagnato, A.; et al. hMENA is a key regulator in endothelin-1/beta-arrestin1-induced invadopodial function and metastatic process. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 3132–3137. [[CrossRef](#)]
194. Schmeichel, K.L.; Beckerle, M.C. The LIM domain is a modular protein-binding interface. *Cell* **1994**, *79*, 211–219. [[CrossRef](#)]
195. Crawford, A.W.; Michelsen, J.W.; Beckerle, M.C. An interaction between zyxin and alpha-actinin. *J. Cell Biol.* **1992**, *116*, 1381–1393. [[CrossRef](#)]
196. Yoshigi, M.; Hoffman, L.M.; Jensen, C.C.; Yost, H.J.; Beckerle, M.C. Mechanical force mobilizes zyxin from focal adhesions to actin filaments and regulates cytoskeletal reinforcement. *J. Cell Biol.* **2005**, *171*, 209–215. [[CrossRef](#)]
197. Wen, X.-M.; Luo, T.; Jiang, Y.; Wang, L.-H.; Luo, Y.; Chen, Q.; Yang, K.; Yuan, Y.; Luo, C.; Zhang, X.; et al. Zyxin (ZYG) promotes invasion and acts as a biomarker for aggressive phenotypes of human glioblastoma multiforme. *Lab. Invest.* **2020**, *100*, 812–823. [[CrossRef](#)]
198. Bravo-Cordero, J.J.; Magalhaes, M.A.O.; Eddy, R.J.; Hodgson, L.; Condeelis, J. Functions of cofilin in cell locomotion and invasion. *Nat. Rev. Mol. Cell Biol.* **2013**, *14*, 405–415. [[CrossRef](#)] [[PubMed](#)]
199. Zhu, B.; Fukada, K.; Zhu, H.; Kyprianou, N. Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. *Cancer Res.* **2006**, *66*, 8640–8647. [[CrossRef](#)]
200. Hensley, P.J.; Zetter, D.; Horbinski, C.M.; Strup, S.E.; Kyprianou, N. Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. *Hum. Pathol.* **2016**, *57*, 68–77. [[CrossRef](#)]
201. Razinia, Z.; Mäkelä, T.; Ylännä, J.; Calderwood, D.A. Filamins in Mechanosensing and Signaling. *Annu. Rev. Biophys.* **2012**, *41*, 227–246. [[CrossRef](#)]
202. Ehrlicher, A.J.; Nakamura, F.; Hartwig, J.H.; Weitz, D.A.; Stossel, T.P. Mechanical strain in actin networks regulates FilGAP and integrin binding to filamin A. *Nature* **2011**, *478*, 260–263. [[CrossRef](#)]
203. Zhou, A.-X.; Hartwig, J.H.; Akyürek, L.M. Filamins in cell signaling, transcription and organ development. *Trends Cell Biol.* **2010**, *20*, 113–123. [[CrossRef](#)]
204. Luo, T.; Mohan, K.; Iglesias, P.A.; Robinson, D.N. Molecular mechanisms of cellular mechanosensing. *Nat. Mater.* **2013**, *12*, 1064–1071. [[CrossRef](#)] [[PubMed](#)]
205. Savoy, R.M.; Ghosh, P.M. The dual role of filamin A in cancer: Can't live with (too much of) it, can't live without it. *Endocr. Relat. Cancer* **2013**, *20*, R341–R356. [[CrossRef](#)]
206. Kamil, M.; Shinsato, Y.; Higa, N.; Hirano, T.; Idogawa, M.; Takajo, T.; Minami, K.; Shimokawa, M.; Yamamoto, M.; Kawahara, K.; et al. High filamin-C expression predicts enhanced invasiveness and poor outcome in glioblastoma multiforme. *Br. J. Cancer* **2019**, *120*, 819–826. [[CrossRef](#)] [[PubMed](#)]
207. Guo, Y.; Li, M.; Bai, G.; Li, X.; Sun, Z.; Yang, J.; Wang, L.; Sun, J. Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer. *Oncol. Lett.* **2018**, *16*, 6261–6266. [[CrossRef](#)]
208. Cui, X.-B.; Zhang, S.-M.; Xu, Y.-X.; Dang, H.-W.; Liu, C.-X.; Wang, L.-H.; Yang, L.; Hu, J.-M.; Liang, W.-H.; Jiang, J.-F.; et al. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma. *J. Transl. Med.* **2016**, *14*, 1–16. [[CrossRef](#)] [[PubMed](#)]
209. Zhang, H.; Yang, W.; Yan, J.; Zhou, K.; Wan, B.; Shi, P.; Chen, Y.; He, S.; Li, D. Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer. *Int. J. Oncol.* **2018**, *53*, 1118–1128. [[CrossRef](#)]
210. Schönichen, A.; Geyer, M. Fifteen formins for an actin filament: A molecular view on the regulation of human formins. *Biochim. Biophys. Acta* **2010**, *1803*, 152–163. [[CrossRef](#)]
211. Young, K.G.; Copeland, J.W. Formins in cell signaling. *Biochim. Biophys. Acta* **2010**, *1803*, 183–190. [[CrossRef](#)] [[PubMed](#)]
212. Baarlink, C.; Wang, H.; Grosse, R. Nuclear Actin Network Assembly by Formins Regulates the SRF Coactivator MAL. *Science* **2013**, *340*, 864–867. [[CrossRef](#)] [[PubMed](#)]